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INTRODUCTION 
 
Hypertension remains the leading cause of death worldwide and one 
of the world's great public health problems(WHO).1 Affecting  1 billion 
people worldwide, systemic hypertension remains the most common, readily 
identifiable and reversible risk factor for myocardial infarction, stroke, heart 
failure, atrial fibrillation, aortic dissection and peripheral arterial disease. 
Because of escalating obesity and population aging in developed and 
developing countries, the global burden of hypertension is rising and 
projected to affect 1.5 billion persons, one third of the world's population, by 
the year 2025.2 
 
Although our understanding of the pathophysiology of essential 
hypertension has increased, the etiology still remains hypothetical. Various 
studies have shown that essential hypertension is associated with     
disturbed calcium metabolism like increased cytosolic calcium and 
decreased serum calcium levels and also increased urinary excretion of 
calcium in patients with essential hypertension.3-6  
 
In this study total serum calcium levels and corrected serum calcium 
levels of essential hypertension patients is compared and correlated with     
matched normotensive controls. Also the calcium levels are compared      
and correlated within the various subsets of hypertensive population viz.. 
age, sex, alcohol, smoking, lifestyle, BMI. 
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AIM  OF  THE  STUDY 
 
1. To compare the total and corrected serum calcium levels between 
patients with newly detected essential hypertension and normotensive 
controls. 
 
2. To compare the total and corrected serum calcium levels of  various 
subsets  of  patients  with  newly  detected  essential hypertension viz.. 
age, sex , smoking , alcohol, life style, BMI. 
 
3. To determine the correlation of total and  corrected serum calcium  
levels with systolic  blood  pressure in patients with essential 
hypertension. 
 
4. To determine the correlation of total and corrected serum calcium 
levels with diastolic blood pressure in patients with essential 
hypertension. 
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REVIEW OF LITERATURE 
 
BLOOD PRESSURE: 
DEFINITION: 7,8
Blood pressure is defined as the lateral pressure exerted by the 
column of blood against any unit area of the vessel wall. It is almost always 
measured in millimetres of mercury (mmHg). 
 
CLASSIFICATION OF BLOOD PRESSURE: 9
TABLE – 1 
Pressure category Systolic BP (mmHg) Diastolic BP (mmHg) 
Normal < 120 < 80 
Prehypertension 120 - 139 80 - 89 
Hypertension 
             Stage  I  
             Stage  II 
 
140-159  
>160 
 
90 – 99 
>100 
 
GUIDELINES FOR MEASUREMENT OF BLOOD PRESSURE:9,10 
PATIENT CONDITIONS: 
 
I . Posture 
 
1. Initially, particularly >65 years, with diabetes, or receiving 
antihypertensive therapy, check for postural changes by taking 
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readings after 5 min supine, then immediately and 2 min after 
standing. 
2. For  routine  follow-up, the patient should sit quietly for 5 min with 
the  arm  bared and  supported  at  the level  of the heart and the back 
resting against a chair. 
 
II . Circumstances 
1. No caffeine or smoking within 30 min preceding the reading. 
2. A quiet, warm  setting. 
 
III . Equipment 
   A . Cuff size 
1. The bladder should encircle atleast 80% of the circumference and 
cover two-thirds of the length of the arm. 
2. Various cuff sizes are available and one should choose appropriate 
cuff according to the individual and site of measurement. 11 
Arm circumference 22 - 26 cm, 12 x 22 cm cuff (small adult) 
Arm circumference 27 - 34 cm, 16 x 30 cm cuff (adult) 
Arm circumference 35 - 44 cm, 16 x 36 cm cuff (large adult) 
Arm circumference 45 - 52 cm, 16 x 42 cm cuff (adult thigh) 
3. A too small bladder may cause falsely high readings. 
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  B . Manometer  
1. Either a mercury,  recently calibrated aneroid or validated electronic 
device. 
 
  C . Stethoscope 
1. The bell of the stethoscope should be use 
2. Avoid excess bell pressure. 
 
IV . Infants 
Use ultrasound (e.g., the Doppler method). 
 
V .Technique 
A . Number of readings 
1. On each occasion, take atleast two readings, separated by as much 
time as is practical; if readings vary >5 mmHg, take additional 
readings until two are close. 
2. For diagnosis, obtain three sets of readings at least 1 week apart. 
3. Initially, take pressure in both arms; if the pressures differ, use the 
arm with the higher pressure. 
4. If the arm pressure is elevated, take the pressure in one leg, 
particularly in patients <30 years old. 
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B . Performance 
1. Inflate the bladder quickly to a pressure 20 mmHg above the systolic 
pressure, recognized by disappearance of radial pulse, to avoid an 
auscultatory gap. 
2. Deflate the bladder 2 to 3 mmHg/second. 
3. Record the Korotkoff phase I (appearance) and phase V 
(disappearance). Phase I corresponds to systolic pressure and phase V 
provides a better measure of diastolic blood pressure. Nevertheless, in 
those conditions where Korotkoff sounds   remain audible despite 
complete deflation of the cuff (aortic regurgitation, arteriovenous 
fistula, pregnancy) phase IV (muffling)  must be used for the diastolic 
measurement. 12 
4. If the Korotkoff  sounds are weak, have the patient raise the    arm 
and open and close the hand 5-10 times, then inflate the bladder 
quickly. 
C .  Recordings  
Note the pressure, patient position, the arm, and cuff size (e.g., 
140/90, seated, right arm, large adult cuff). 
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HYPERTENSION 
DEFINITION: 
Hypertension  currently is defined as a usual BP of 140/90 mmHg or 
higher, BP levels  for which the benefits of pharmacological treatment have  
been definitively established in randomized placebo-controlled trials.2 
Clinically, hypertension  might  be defined as that level of blood pressure at  
which the institution of therapy reduces blood pressure related morbidity 
and mortality. 13
EPIDEMIOLOGY: 
 From an epidemiologic perspective, there is no obvious level of 
blood pressure  that  defines hypertension. In  adults,  there is a continuous, 
incremental  risk  of  cardiovascular  disease, stroke, and  renal disease with 
increasing  levels of both systolic and diastolic blood pressure. 
 
 
The overall prevalence of hypertension varies from 6 – 32 % 14 thus 
affecting 1 billion population worldwide. In India the prevalence of 
hypertension is 59.9 and 69.9 per 1000 in males and females in urban 
population  while  it  is  35.5  and  35.9  per 1000 in  males and females in 
rural population respectively.15 
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Depending on etiology hypertension can be divided into two types. 
1. Primary or essential hypertension. 
2. Secondary hypertension. 
 
PRIMARY (ESSENTIAL) HYPERTENSION: 
DEFINITION :16  
Primary  hypertension, which accounts for 95 percent of all cases of 
hypertension, has been traditionally defined as high blood pressure for 
which an obvious secondary cause (e.g., renovascular disease, 
aldosteronism, pheochromocytoma, or gene mutations) cannot be 
determined . 
 
  Although primary hypertension is a heterogeneous disorder, some   of 
the main causes of high blood pressure in primary hypertension are known. 
For example, overweight and obesity may account for as much as 65 to 75% 
of the risk for primary hypertension. Other factors, such as sedentary 
lifestyle, excess intake of alcohol or salt, and low potassium intake, are also 
known to increase blood pressure in many patients  who are  classified  as 
having  primary  hypertension. 
 
 
MECHANISMS  OF  PRIMARY(ESSENTIAL) HYPERTENSION :2
A  multitude  of  neurohormonal , renal, and vascular mechanisms 
interact to varying degrees in contributing different hemodynamic forms   of 
hypertension. 
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NEURAL MECHANISMS:  
In young adults, primary hypertension consistently is associated with 
increased  heart  rate and cardiac output, plasma and urinary norepinephrine 
levels, regional norepinephrine spillover, peripheral postganglionic 
sympathetic nerve firing (by microelectrode recordings)  and alpha-
adrenergic receptor–mediated vasoconstrictor tone in the peripheral 
circulation.17 Sympathetic overactivity has also been demonstrated in several 
other forms of established human hypertension like, hypertension  
associated with obesity, sleep apnoea, early type 2 diabetes mellitus and 
prediabetes, chronic kidney disease, heart failure and immunosuppressive 
therapy with calcineurin inhibitors such as cyclosporine. In these conditions, 
central sympathetic outflow can be driven by deactivation of inhibitory 
neural inputs (e.g., baroreceptors), activation of excitatory neural inputs 
(e.g., carotid body chemoreceptors, renal afferents) or by circulating  
angiotensin II, which activates pools of excitatory brain stem neurons that 
are devoid of a blood-brain barrier. 
 
BARORECEPTORS: 
In hypertension, the  baroreceptors  are reset to  defend a higher level 
of  BP. Baroreflex control  of  sinus node  function  is impaired even in mild  
hypertension  but  baroreflex control of systemic vascular resistance and BP 
is well preserved. Surgically-implanted carotid baroreceptor pacemakers 
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produce sustained BP reductions in dog models of hypertension18 and 
parallel multicenter clinical trials are currently underway in patients with 
medically refractory hypertension. 
 
Partial baroreceptor dysfunction is common in elderly hypertensives 
and typically presents with a triad of orthostatic hypotension, supine 
hypertension  and  symptomatic postprandial hypotension, the latter initiated  
by splanchnic  pooling  after carbohydrate-rich meals.19 
 
RENAL MECHANISMS:  
The kidney is the culprit and victim in hypertension, producing a 
vicious cycle of progressive renal dysfunction and hypertension. In many 
forms of experimental and human hypertension, the fundamental 
abnormality is an acquired or inherited defect in the kidney's ability to 
excrete the excessive sodium load imposed by a modern high salt diet. Renal 
sodium retention expands the plasma volume, increasing cardiac output and 
triggering autoregulatory responses that increase systemic vascular 
resistance. Salt retention also augments the smooth muscle contraction 
produced by all known endogenous vasoconstrictor   substances. 
 
Resetting of Pressure natriuresis: 
In normotensive individuals, BP elevation invokes an immediate 
increase in renal sodium excretion to shrink plasma volume and return BP to 
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normal. In almost all forms of hypertension, the pressure-natriuresis curve is 
shifted to the right and, in salt-sensitive hypertension, the slope is reduced. 
Resetting of the pressure-natriuresis curve leads to nocturia, one of the most 
common and bothersome symptoms in patients with uncontrolled 
hypertension. Hypertensive individuals excrete the same amount of a given 
dietary sodium load as normotensive individuals, but at a higher BP, and 
require many more hours to excrete the sodium load and achieve sodium 
balance. 
Low birth weight:  
Low birth weight with reduced nephrogenesis increases the risk of 
developing adult salt-dependent hypertension. Adult hypertensives have 
fewer glomeruli per kidney but very few obsolescent glomeruli, suggesting 
that nephron dropout and decreased total filtration surface area is the cause 
and not the consequence of the hypertension .20
GENETIC CONTRIBUTIONS: 
Animal and human studies have implicated an important genetic 
contribution to salt-sensitive hypertension. Rats with inbred defects in the 
kidney's ability to excrete sodium remain relatively normotensive on a 
sodium-restricted diet but become severely hypertensive when fed a high-
sodium diet, a model of salt-sensitive hypertension that can be cured by 
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renal transplantation. A similar gene-environment interaction has been 
postulated to explain why persons of sub-Saharan African ancestry remain 
normotensive on a sodium-restricted diet in rural Africa but are predisposed 
to hypertension when exposed to a high-sodium western diet. However, 
sodium sensitivity of BP can be acquired without invoking any genetic 
contribution. With long-standing hypertension, BP becomes increasingly 
salt-sensitive as renal function declines in patients of all ethnic backgrounds. 
 
VASCULAR MECHANISMS: 
Alterations in the structure and function of small and large arteries 
play a pivotal role in the pathogenesis and progression of hypertension. 
 
Endothelial dysfunction:  
 
The endothelial lining of blood vessels is critical to vascular health 
and constitutes a major defence against hypertension. Dysfunctional 
endothelium is characterized by impaired release of endothelial-derived 
relaxing factors (e.g., NO, endothelium-derived hyperpolarizing factor) and 
enhanced release of endothelium-derived constricting, proinflammatory, 
prothrombotic and growth factors. The latter include endothelin, 
thromboxane   and TGF-β .21 
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The endothelium of all blood vessels expresses the enzyme nitric 
oxide synthase (NOS), which can be activated by bradykinin or 
acetylcholine or by the cyclic laminar shear stress that accompanies 
hypertension, particularly with the widened pulse pressure in ISH. Once 
activated, NOS converts l-arginine to citrulline, an inert substance and nitric 
oxide (NO), a volatile gas that diffuses to the adjacent vascular smooth 
muscle and activates a series of G kinases that culminate in vasodilation . 
 
In humans,  endothelium-dependent  vasodilation  can be assessed by  
measuring  increases in the large artery  (forearm or coronary) diameter 
following  intraarterial infusion of acetylcholine or release of  ischemia (e.g., 
arrested forearm circulation) or a sudden elevation in BP (cold pressor test). 
Competitive inhibitors of NOS specifically block endothelium-dependent 
dilation but do not block the dilation of these arteries produced by 
exogenous nitrovasodilators (e.g., nitroglycerin, nitroprusside). These 
measurements most often are obtained with brachial artery ultrasound. More 
accurate measurements require invasive techniques. 
 
C-reactive protein (CRP) is an easily measured serum biomarker for 
determining blood vessel inflammation and endothelial dysfunction.22 
Cross-sectional studies have shown strong correlations between elevated 
CRP and arterial stiffness and elevated pulse pressure. Longitudinal studies 
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have implicated elevated CRP levels as a risk factor for new onset of 
hypertension and accelerated progression of hypertensive target organ 
disease, possibly beyond that explained by BP elevation alone. 
 
 One of the principal mechanisms of endothelial cell dysfunction in 
hypertension is the production of superoxide anion and other reactive 
oxygen species that quench  NO, thereby reducing its bioavailability. There 
are three main enzymatic sources of vascular superoxide:(1) NADPH 
oxidases, which are universally expressed in all vascular cell types and 
activated by circulating A II; (2) NOS, which produces superoxide only 
when an important cofactor (tetrahydrobiopterin) is deficient(NOS 
uncoupling); and (3) xanthine oxidase, which produces uric acid.23 
 
 Generation of reactive oxygen species by xanthine oxidase almost 
certainly accounts for the associations among elevated serum uric acid levels 
and hypertension .24 However, uric acid  itself is an antioxidant. Thus the 
xanthine oxidase inhibitor allopurinol does not consistently lower BP in 
patients with hypertension because the drug simultaneously reduces both 
these opposing effects on vascular function .25 
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Vascular remodelling:  
Over time, endothelial cell dysfunction, neurohormonal activation and 
elevated BP cause remodelling of blood vessels, which further perpetuates 
the hypertension .26 An increase in the medial thickness relative  to lumen 
diameter (increased media-to-lumen ratio) is the hallmark of hypertensive 
remodelling in small and large arteries. Small artery remodelling is initiated 
by vasoconstriction, which normalizes wall stress  and  averts a trophic 
response. Normal smooth muscle cells rearrange themselves around a 
smaller lumen diameter; a process termed inward eutrophic remodelling. 
The media-to-lumen ratio increases but the medial cross-sectional area 
remains unchanged. By decreasing lumen diameter in the peripheral 
circulation, inward eutrophic remodelling increases systemic vascular 
resistance, the hemodynamic hallmark of diastolic hypertension. 
 
In contrast, large artery remodelling is characterized by the expression 
of hypertrophic genes, triggering increases in medial thickness as well as the 
media-to-lumen ratio. Such hypertrophic remodelling involves not only an 
increase in the size of vascular smooth muscle cells but also an 
accumulation of extracellular matrix proteins such as collagen and 
fibronectin, because of activation of TGF- β. The resultant large artery 
stiffness is the hemodynamic hallmark of ISH. 
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Antihypertensive therapy may not provide optimal cardiovascular 
protection unless vascular remodelling is prevented or reversed by 
normalizing hemodynamic load, restoring normal endothelial cell function, 
and eliminating the underlying neurohormonal activation .26 
 
HORMONAL MECHANISMS: 
 Renin-Angiotensin-Aldosterone System. 
Activation of the renin-angiotensin-aldosterone system (RAAS) is one 
of the most important mechanisms contributing to endothelial cell 
dysfunction, vascular remodelling, and hypertension. Renin, a protease 
produced solely by the renal juxtaglomerular cells, cleaves angiotensinogen 
to Angiotensin I(A I), which is converted by angiotensin-converting enzyme 
to Angiotensin II(A II) . Chymase, a serine protease in       the heart and 
systemic arteries, provides an alternative pathway for conversion of 
Angiotensin I to Angiotensin II. The interaction of A II with G protein–
coupled AT1 receptors activates numerous cellular processes that contribute 
to hypertension and accelerate hypertensive end-organ damage. These 
include vasoconstriction, generation of reactive oxygen species, vascular 
inflammation, vascular and cardiac remodelling, and production of 
aldosterone, the principal mineralocorticoid. There is increasing evidence 
that aldosterone, A II, and even renin and prorenin activate multiple 
signaling pathways that can damage vascular health and cause hypertension. 
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Aldosterone and ENaC Regulation:  
RAAS activation is a major homeostatic mechanism to counter 
hypovolemic hypotension (as with hemorrhage or salt and water 
deprivation). Interaction of aldosterone with cytosolic mineralocorticoid 
receptors in the renal collecting duct cells recruits sodium channels from the 
cytosol to the surface of the renal epithelium. The epithelial sodium 
channels (ENaCs) so recruited increase sodium reabsorption, thereby 
reexpanding plasma volume. Conversely, modern high-salt diets should 
engender continual feedback inhibition of the RAAS. Suppression of serum 
aldosterone should trigger sequestration of ENaCs by endocytosis and 
increased renal sodium excretion, thereby shrinking plasma volume to 
protect against salt-sensitive hypertension. 
Thus, in the setting of high dietary sodium and elevated BP, the 
RAAS should be completely suppressed and any degree of RAAS activity is 
inappropriate. In normotensive individuals, the risk of developing 
hypertension increases with increasing levels of serum aldosterone that are 
well within the normal range .27 In African Caribbean hypertensives, serum 
aldosterone levels are higher than in white hypertensives despite lower 
plasma renin levels 28, implicating abnormal aldosterone production by 
renin-independent mechanisms, a forme fruste of primary aldosteronism. By 
stimulating mineralocorticoid receptors in the heart and kidney, circulating 
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aldosterone may contribute to the development of cardiac and renal fibrosis 
in hypertension .29 By stimulating mineralocorticoid receptors in the brain 
stem, aldosterone also may contribute to sympathetic overactivity. 
Receptor mediated actions of angiotensin II:  
Two main types of angiotensin receptors are known. AT1 receptors 
are widely expressed in the vasculature, kidney, adrenals, heart, liver and 
brain. AT 1 receptor activation explains most of the hypertensive actions of 
A II. Furthermore, constitutes a major therapeutic target for interrupting 
every step in cardiovascular disease progression, from vascular remodelling 
and formation of atherosclerotic plaque to stroke, myocardial infarction (MI) 
and death. In contrast, AT2 receptors are widely distributed in the fetus but 
in adults, are found only in the adrenal medulla, uterus, ovary, vascular 
endothelium and distinct brain regions. In rodents, AT2 receptor activation 
opposes some of the deleterious effects of AT1 receptors by promoting  
endothelium-dependent  vasodilation by bradykinin and nitric oxide 
pathways. However, recent animal studies have suggested that AT2 receptors 
can be profibrotic but their role in human hypertension  remains  speculative 
Receptor mediated actions of renin and prorenin:  
In the traditional RAAS, prorenin has been considered to be the 
inactive precursor of renin, which functions solely to generate A I by 
19 
 
enzymatic cleavage of angiotensinogen. These concepts are rapidly evolving 
as newer studies implicate prorenin and renin as direct cardiac and renal 
toxins. Prorenin is inactive because a 43–amino acid hinge is closed and 
prevents it from binding to angiotensinogen. In the kidneys, inactive 
prorenin is converted to active renin when this inhibitory hinge region is 
enzymatically cleaved. When circulating prorenin binds to a newly 
discovered (pro)renin receptor in the heart and kidneys, the hinge is opened 
(but not cleaved), and this nonenzymatic process fully activates               
prorenin .30,31 As a result, TGF- β production is accelerated, leading to 
collagen deposition and fibrosis. This receptor-mediated process is 
completely independent of A II generation and therefore unaffected by 
angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor 
blockers (ARBs). Although ACEIs and ARBs are excellent 
antihypertensives , they trigger large reactive increases in prorenin and renin 
production that may counter some of the cardiovascular protection afforded 
by reduced AT1 receptor activation. 
OTHER MECHANISMS: 
Heredity: 
 Genetic factors have long been assumed to be important in the genesis 
of hypertension. This view is supported by animal studies as well as 
population studies. One approach has been to assess the correlation of blood 
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pressure within families (familial aggregation) .32 From these studies, the 
minimum size of the genetic factor can be expressed by a correlation 
coefficient of approximately 0.2. However, the variation in the size of the 
genetic factor in different studies reemphasizes the likely heterogeneous 
nature of the essential hypertensive population. Most studies support the 
concept that the inheritance is probably multifactorial. Now monogenic 
defects have been reported which have one of their consequences, an 
increased arterial pressure33 e.g. Liddle’s syndrome. Suseptibility genes have 
now been reported 34 e.g. Angiotensinogen gene and α – adducing gene.  
 
Environment :32 
A number of environmental factors have been implicated in 
development of hypertension, including salt intake, obesity, stress, 
alcoholism, family size and crowding. These factors all have been assumed 
to be important in the rise in blood pressure with age in more affluent 
societies, in contrast to the decline in blood pressure with age in more 
primitive cultures.   
 
Insulin resistance: 
Insulin resistance and/or hyperinsulinemia have been suggested as 
being responsible for the increased arterial pressure in some patients with 
hypertension. Insulin resistance is common in patients with type 2 diabetes 
21 
 
mellitus or obesity.35 A diminished activity of calmodulin-stimulated   Ca2+-
ATPase despite increased levels of insulin, a known activator of this pump, 
further suggesting the presence of insulin resistance in normotensive 
offsprings of essential hypertensive individuals. Since Ca2+-ATPase is     an 
extrusion pump, a drop in its activity may lead to an increase in intracellular 
calcium accumulation and thus contribute to the    development of 
hypertension.36 Also hyperinsulinemia causes renal sodium retention and 
increases sympathetic activity. It also causes  smooth muscle hypertrophy 
due to mitogenic action of insulin.  
 
OVERVIEW OF PATHOGENESIS :10
Hundreds of papers have been published describing the work of 
thousands of investigators who have spent many millions, perhaps billions, 
of dollars, yet the pathogenesis of primary hypertension is as elusive and 
enigmatic as ever. The pressure required to move blood through the 
circulatory bed is provided by the pumping action of the heart [cardiac 
output (CO)] and the tone of the arteries [peripheral resistance (PR)]. Each 
of these primary determinants of BP is, in turn, determined by the 
interaction of the exceedingly complex series of factors displayed in part in 
figure 1. 
Hypertension has been attributed to abnormalities in virtually every 
one of these factors. Each will be examined and attempts will be made along 
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the way to integrate them into logical hypotheses. It is unlikely that all these 
factors are operative in any given patient; but multiple hypotheses may 
prove to be correct, because the hemodynamic hallmark of primary 
hypertension - a persistently elevated vascular resistance, may be reached 
through a number of different paths. Before the final destination, these may 
converge into either structural thickening of the vessel walls or functional 
vasoconstriction. Moreover, individual factors often interact and the 
interactions are proving to be increasingly complex. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pathogenesis  of  Primary Hypertension . 
We will follow the outline shown in Figure 1, recognizing that the 
position of each factor in the outline is not necessarily in the order that the 
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hemodynamic cascade follows in the pathogenesis of hypertension. Without 
knowing what starts the process, we can lay out only a preliminary blueprint 
that can be used by beginning at multiple sites. 
 Risks Influencing Prognosis in Patients with Hypertension :37
Risk Factors for Cardiovascular Disease: 
  Levels of systolic and diastolic blood pressure  
  Age (yr) — men  > 55; women  > 65  
  Smoking  
  Dyslipidemia  
  Family  history  of  premature  cardiovascular disease  
  Abdominal obesity  
  Diabetes mellitus  
  CRP  ≥1 mg/dl 
Subclinical Target Organ Damage: 
 Left ventricular hypertrophy  
Ultrasound evidence of arterial wall thickening or      
atherosclerotic plaque 
Estimated glomerular filtration rate ≤60 ml/min/1.73 m2  
 Microalbuminuria 
Clinical Target Organ Damage:  
Cerebrovascular disease  
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Ischemic stroke  
Cerebral hemorrhage  
Transient ischemic attack  
Heart disease  
Myocardial infarction or acute coronary syndrome  
Angina  
Coronary revascularization  
Congestive heart failure  
Renal disease  
Diabetic nephropathy  
Chronic kidney disease  
Proteinuria (>300 mg/24 hr)  
Peripheral arterial disease  
Advanced retinopathy  
Hemorrhages or exudates  
Papilledema  
 
SECONDARY HYPERTENSION :38
In 5 – 10% of  patients the causes of hypertension can be identified, 
and some are curable. By definition, these are designated as secondary 
hypertension. 
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CAUSES OF SECONDARY HYPERTENSION:38 , 39
Renal disorders:
Renal parenchymal 
 Acute and chronic glomerulonephritis; pyelonephritis; 
nephrocalcinosis; neoplasms; glomerulosclerosis; interstitial, 
hereditary or radiation nephritis. 
 Obstructive uropathies and hydronephrosis 
 Renin-secreting renal tumors (hemangiopericytoma, Wilms or renal 
cell, pancreatic, ovarian tumors) 
 Congenital defect in renal Na transport (Liddle's syndrome) 
 Renal trauma 
 
Renovascular 
• Renal arterial lesions, occlusions, stenoses, aneurysms, 
thromboses 
• Renal vasculitis or glomerulitis 
• Coarctation of the aorta with renal ischemia 
• Aortitis with renal ischemia 
 
Adrenocortical disorders: 
 Cushing syndrome (cortisol excess) 
 Primary aldosteronism due to adenoma (Conn syndrome) 
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 Pseudoprimary aldosteronism (bilateral adrenocortical hyperplasia) 
 Congenital or acquired enzymatic defects with excess Na+-retaining 
steroids (11β-hydroxylase deficiency; 11β-hydroxysteroid 
dehydrogenase deficiency, 17α-hydroxylase deficiency) 
 Adrenal carcinoma 
 Ectopic corticotropin-secreting tumor 
 
Pheochromocytoma (adrenal medullary or extraadrenal chromaffin   
tumors) 
 
Other endocrine causes: 
 Hypothyroidism (diastolic hypertension) 
 Hyperthyroidism (systolic hypertension) 
 Hypercalcemic states, hyperparathyroidism 
 Acromegaly 
 
Toxemias of pregnancy 
Neurogenic factors: 
 Increased intracranial pressure 
 Familial dysautonomia 
 Acute porphyria, buffer denervation, poliomyelitis, spinal cord 
injuries 
 Psychogenic 
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Iatrogenic and other causes: 
 Oral contraceptive or estrogen therapy 
 Mineralocorticoid or glucocorticoid therapies, licorice ingestion 
(i.e., acquired 11β-hydroxysteroid dehydrogenase deficiency) 
 Sympathomimetic drugs (decongestant) 
 Antidepressants 
 Alcohol abuse 
 Lead toxicity 
 Monoamine oxidase inhibitors (interactions with other agents) 
 Excessive salt appetite 
 
ROLE OF CALCIUM  IN  ESSENTIAL HYPERTENSION: 
 
There are several hypothesis that abnormalities of calcium 
homeostasis  at  both  an organ and cellular level as a primary factor in the 
pathogenesis of human and experimental hypertension .Also a low calcium 
intake has been associated with increase in blood pressure in several 
epidemiological studies. 
 
An increase in leucocyte cytosolic calcium levels has been reported in 
some hypertensives, similarly an increase in RBC and platelet cytosolic 
calcium levels has also been reported in some hypertensives.40 Several 
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studies have reported a potential link between the salt sensitive forms of 
hypertension and calcium. 
 
It has been postulated that with salt loading and defect in the kidney’s 
ability to excrete , a secondary increase in circulating natriuretic factors may 
occur .One of these, the digitalis like natriuretic factor   inhibits ouabain 
sensitive Na+-K+ATPase causing intracellular calcium accumulation and 
hyperreactive vascular smooth muscle.41,42 
 
In  one third of  patients  with  hyperparathyroidism, hypertension is 
noted and can be attributed to renal parenchymal demage due to 
nephrolithiasis and nephrocalcinosis. However increased calcium levels also 
have a direct vasoconstrictive effect. In some cases hypertension can be 
treated by correcting hypercalcemia.43 Additional studies are needed to 
resolve these seemingly conflicting observation. 
 
CALCIUM IN PATHOGENESIS OF PRIMARY HYPERTENSION: 
The calcium status of humans with essential hypertension and genetic 
animal models of hypertension is characterized by low serum ionized 
calcium concentration, increased urinary calcium excretion, and increased 
parathyroid hormone (PTH) concentration. Calcitriol metabolism and bone 
mineralization are also altered in hypertension. These alterations in systemic 
calcium metabolism may be linked to factors responsible for the elevated 
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blood pressure. Cytosolic free calcium tends to be increased in most cells 
that have been studied from hypertensive humans and animals. Changes in 
cellular calcium metabolism may be partly mediated by calcium-regulating 
hormones that tend to be elevated in essential hypertension such as PTH and 
calcitriol.44 This raised levels may be due to an intrinsic defect in renal 
calcium handling.45 Administration of supplemental dietary calcium tends to 
suppress PTH, calcitriol, and intracellular free calcium. 
 
In hypertensive patients there is a defect in excreting the digitalis like 
natriuretic factor  which  inhibits ouabain sensitive Na+-K+ATPase  causing 
intracellular sodium accumulation. This increased intracellular sodium 
causes intracellular calcium accumulation  in the vascular smooth muscle 
cells leading to an increase in contractility and vascular tone, resulting in 
increased peripheral resistence and blood pressure.42 
 
There exists  numerous relationship between calcium and sodium as 
stated by Blaustein.46 
a. Inhibition of N+-K+ Exchange pumps would depolarise muscle 
fibres and thereby increase calcium entry through voltage 
sensitive calcium channels. 
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b. An increase in intracellular sodium will result in a sodium 
electrochemical gradient between sarcoplasm and external 
medium causing reduced extrusion of calcium from the cell. 
c. An increase in intracellular sodium in the presynaptic terminal 
of sympathetic neurons promoting calcium dependant 
noradrenaline release causing release of calcium from cellular 
stores. 
d. A very small rise in intracellular sodium, theoretically is 
adequate to cause enough rise in intracellular calcium, to 
increase the resting vascular smooth muscle tone by 50%. 
 
 
Defects of Calcium at Cellular level in Humans: 
Several defects in cellular calcium concentration, membrane binding, 
and transport kinetics have been identified in red blood cells (RBCs), 
platelets, and adipocytes of persons with essential hypertension, including 
reduced calcium buffering and sodium-calcium exchange. In RBCs of 
hypertensive persons, the amount of calcium bound to the inside surface is 
reduced by 25 to 30%.47,48 This decrease in membranebound calcium has 
been linked to increased permeability of the cell to sodium and partial 
inhibition of Na+-K+ ATPase activity. 
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While calmodulin content and distribution in RBCs from hypertensive 
subjects have been found to be normal, the ability of calmodulin to activiate 
Ca2+-ATPase is impaired, since the affinity of the calcium pump for calcium 
is reduced and the maximal activity of the pump is lower.49 It was also 
demonstrated that basal (unstimulated) Ca2+-ATPase  activity is decreased in 
RBC membranes of hypertensive subjects compared with that in matched 
control subjects.50 A diminished Ca2+-ATPase or calmodulin  stimulated  
Ca2+-ATPase has been demonstrated in platelets and erythrocytes obtained 
from primary hypertensive subjects.51 The collective observations suggest a 
fundamental alteration in the hypertensive subject’s inner membrane 
calcium-calmodulin binding kinetics and subsequent activation of energy 
dependent cation pumps such as  Ca2+-ATPase.52
 Intracellular free calcium concentrations are increased in platelets  of 
subjects with high blood pressure. Those with higher intracellular free 
calcium concentrations were associated with lower extracellular calcium 
levels, which demonstrates the dichotomy that can exist between these 
calcium pools. Calcium homeostasis of platelets is dependent on limiting 
membrane fluxes, stimulating efflux and promoting sarcoplasmic reticulum 
sequestration,53 all being calcium- calmodulin- dependent processes. 
 
 Since Ca2+-ATPase is of fundamental importance in the final 
regulation of normal cytosolic calcium content and if the RBC defects in 
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calcium binding and Ca2+-ATPase activation are reflective of a more 
generalized  membrane-associated defect, then it follows that intracellular 
free calcium would be modestly elevated in platelets. The possibility that a 
generalized defect does exist is supported by two additional observations: 
the intracellular calcium concentrations are elevated in RBCs of 
hypertensive persons 54 and adipocytes obtained from hypertensive subjects 
exhibit similar alterations of intracellular calcium.55 
 
Effects of reduced calcium intake: 
Various studies showed an association between dietary calcium intake 
and blood pressure however, the potential benefit of treating hypertension 
with increased dietary intake of calcium remain  controversial. Previous 
analyses of the NHANES I and II data have yielded conflicting findings 
regarding the influence of various dietary variables on blood pressure, 
particularly calcium.56 Many cross-sectional studies have shown relations 
between dietary calcium intake and blood pressure.57,58 Data from the 
Western Electric Heart Study  59 showed that calcium intake was inversely 
related to the incidence of elevated DBP (95 mmHg or greater) but not of 
elevated SBP (160 mmHg or greater). A recent report of a large cohort study 
of women showed that dietary calcium intake was inversely related to 
hypertension among women.60 
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Increased urinary calcium excretion: 
The total and fractional urinary calcium excretion is elevated in 
subjects with essential hypertension.6 Consistent with these reports is a 
population survey that demonstrated a positive correlation between urinary 
calcium excretion and blood pressure among 9321 men.61 Although dietary 
calcium was not measured in the survey, the greater urinary calcium 
excretion was thought to be reflective of a greater dietary intake of calcium. 
The likelihood of this cause-and effect relationship's holding is inconsistent 
with the epidemiological data summarized above, which report decreased 
intake of calcium by hypertensive persons. 
 
 In addition, in an intervention trial, which assessed urinary calcium 
and dietary calcium intake in hypertensive subjects had observed that lower 
intakes were associated with higher excretion rates.62 Whether the excessive 
urinary calcium excretion reflects an enhanced intestinal absorption of a 
decreased oral intake or a decreased ability of the kidney to reabsorb the 
cation is controversial. However the pattern of increased PTH levels and 
urinary cyclic AMP, lower serum ionized calcium values and reduced serum 
phosphorus levels appears to argue strongly against the former and in   
favour of the latter possibility.  
 
 
 
34 
 
Calcium supplements: 
In 42 mostly short-term studies of either calcium supplements (33) or 
dietary intervention (9) in 4560 nonpregnant adults, the blood pressure 
reduced by 1.44/0.84 mmHg.63 Because calcium supplements sometimes 
raise blood pressure and increase the risk of kidney stones, the best    course 
is to ensure that calcium intake is not inadvertently reduced by       reduction  
of milk and cheese consumption in an attempt to reduce saturated fat and 
sodium intake.  
 
Supporting literatures :  
Some epidemiological studies are discussed here to enlighten the present 
study.  
K. Sudhakar et al.,5 in their study enrolled one hundred and seventeen 
confirmed untreated essential hypertensive patients referred from cardiology 
unit of Osmania University General Hospital and  Osmania University 
Health Centre, Hyderabad and their 77 first degree relatives (33 siblings and 
44 offsprings). One hundred and sixty persons with normal BP and without 
family history of hypertension were taken as normotensive age and sex 
matched controls.The mean total serum calcium levels in males and females  
were significantly  decreased in hypertensive group when compared with 
normotensive controls. In the first-degree relatives also the total serum 
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calcium levels were significantly decreased  when compared with the 
controls. 
 
AR Folsom et al.,64 studied the serum calcium fractions in essential 
hypertensive and matched normotensive subjects. In the study, the 
hypertensive group comprised 28 subjects whose diastolic blood pressure on 
both occasions was greater than 90 mm Hg and who were not taking 
antihypertensive medication. One normotensive control was matched to each 
hypertensive subject. Controls were required to be of the same race, age and 
sex as the matched hypertensive subject. Hypertensive subjects had lower 
mean serum levels of ultrafilterable calcium, and ionized calcium.Calculated 
serum concentrations of complexed calcium were significantly lower in 
hypertensive subjects, while proteinbound calcium concentrations were 
higher. Serum phosphorus,serum albumin and dietary calcium intake, were 
not different between the two groups. 
 
Fu, Y., Wang, S.,et al65  assessed the relationships between plasma 
and intracellular Ca2+ ,Mg2+ and blood cell membrane ATPase activity  in  
normotensive  and  hypertensive subjects in their study, which suggested 
that the hypertensive group consistently demonstrated a significant 
decreased activity of ATPase along with significantly lower plasma calcium 
and higher cytosolic calcium levels when compared with those    in 
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normotensive group. No significant differences were found in either plasma 
magnesium or intracellular magnesium level between the two groups. This 
study conducted in China included 55 patients with essential hypertension 
and 32 normotensive controls. 
 
Strazzullo P et al.,66 Erne P., Bolli P., et al.,67 Touyz, R.M.,et al.,4 also 
reported a decrease in the total serum calcium concentration in essential 
hypertensive patients in their corresponding studies.While  McCarron DA., 
68 and Resnick LM, Laragh JH.,et al69  noted that essential hypertensive 
subjects had a lower serum ionized calcium concentrations , compared with 
normotensive  subjects, even when total calcium levels were similar.  
 
Grobbee DE et al.,70 in his research article  “Calcium metabolism and 
familial risk of hypertension” stated that there is circumstantial evidence that 
disturbances of calcium metabolism are implicated in primary hypertension. 
From a large number of  epidemiological studies, data have shown that a 
low dietary calcium intake increases the risk for high BP. There is no 
general sensitivity for the effects of inadequate calcium intake,but subgroups 
of hypertensive patients have been described, characterized by reduced 
serum ionized calcium levels, increased urinary excretion of calcium, raised 
intracellular calcium levels, reduced cellular membrane calcium binding, 
and other indicators of a relative calcium need. Some of these changes, 
however, may be secondary to blood pressure elevation.The family history 
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approach enables to study the pathophysiology of early primary 
hypertension, at a stage at which BP differences between future hypertensive 
subjects and normotensive subjects are still limited.  
 
He  also stated that in the “Dutch Hypertension and Offspring     
Study”, young normotensive subjects were selected on the basis of  presence 
or absence of familial predisposition for hypertension. The findings showed 
that disturbances in calcium metabolism were present in the early phase of 
primary hypertension and may precede the development of high BP. 
Moreover, they suggested that changes in calcium metabolism may be a 
characteristic of familial hypertension and could reflect a genetic basis for 
calcium sensitive hypertension. The presence of  a relatively reduced serum 
calcium and increased plasma PTH  level in the offspring of hypertensive 
parents indicates that calcium balance in prehypertensive subjects is 
maintained at a higher level of circulating PTH. 
 
Oshima T et al.,71 in his research article “Systemic and cellular 
calcium metabolism and hypertension” which he submitted to ‘The 
Seminars in Nephrology 1995’ mentioned that the calcium status of humans 
with essential hypertension and genetic animal models of hypertension is 
characterized by low serum ionized calcium concentration, increased urinary 
calcium excretion, and increased PTH concentration. These alterations in 
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systemic calcium metabolism may be linked to factors responsible for the 
elevated blood pressure. Cytosolic free calcium tends  to be increased in 
most cells that have been studied from hypertensive humans and animals. 
Changes in cellular calcium metabolism may be partly mediated by calcium-
regulating hormones that tend to be elevated in essential hypertension such 
as PTH and calcitriol. Administration of supplemental dietary calcium tends 
to suppress PTH, calcitriol, and intracellular free calcium. Further research 
is need concerning the observed association among systemic markers of 
calcium metabolism, cellular calcium metabolism, and arterial blood 
pressure regulation. 
 
Various studies had showed an association between dietary calcium 
intake and blood pressure but the potential benefit of treating hypertension 
with increased dietary intake of calcium remain controversial. However 
there are certain populations which can be benefited from calcium 
supplementation. 
 
Hojo, M.et al.,72 in his study mentioned approximately 10% of 
pregnancies are accompanied by HT, pre-eclampsia accounting for 50% 
cases . Women at risk of developing PIH are typically responsive to 
increased calcium intake, with the incidence of hypertension being  reduced 
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upto 40-50% in those with a 1500-2000 mg/day intake (there is   an 
increased daily calcium requirement due to fetal processes). 
 
Patients with salt-sensitive hypertension represent another group   for 
whom increased calcium intake appears to be highly beneficial. Responses 
in blood pressure to salt  ingestion have been shown to additionally depend 
on the adequacy of dietary mineral intake (calcium, magnesium, and 
potassium). In fact, in the NHANES I database, several individuals with 
high sodium intake were observed to have lower blood pressures than would 
be expected; upon further analysis it was found that the calcium and 
potassium intake of these individuals was high, revealed in a study by 
McCarron, D.A.et al.,73 
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MATERIALS AND METHODS 
 
This study was carried out in Department of General Medicine at 
Government Kilpauk Medical College & Hospital,Chennai – 10  during the 
period between January 2009 and October 2009.This study was ethically 
approved by the Ethical committee of Government Kilpauk Medical College 
and Hospital, Kilpauk, Chennai – 10. 
 
This study is a cross sectional study, with cases and controls enrolling 
100 newly detected essential hypertension patients as cases and 50 suitable 
healthy individuals with normal blood pressure as controls, as per JNC-7 
guidelines. Cases were selected from those who visited hypertension clinic 
and those who were admitted in wards during the study period. Controls 
were selected from those who attended medical outpatient department for 
minor ailments and healthy volunteers. 
 
INCLUSION CRITERIA: 
1.  Newly detected essential hypertension patients. 
 
EXCLUSION CRITERIA: 
1. Essential hypertension. 
             a. Known cases of hypertension. 
             b. Patients on antihypertensive agents. 
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             c. Patients with malignant hypertension. 
 
2. Chronic renal failure. 
3. Diabetes mellitus. 
4. Ischemic heart disease. 
5. Patients on hypertension inducing drugs. 
6. Other causes of secondary hypertension. 
7. Congestive cardiac failure. 
8. Cerebrovascular accident. 
9. Peripheral vascular disease. 
10. Patients with acute illness. 
11. Patients with any medical or surgical complications. 
12. Adolescents and young adults < 30 yrs. 
13. BMI < 18.5Kg/m2. 
Applying these criteria,100 essential hypertensive patients were 
selected and included in the study after informed consent (Group A). 
Similarly 50 normotensive controls were selected and involved in the study 
after informed consent(Group B). 
Secondary hypertension patients were excluded from the study by 
detailed history and clinical examination and also with relevant 
haematological, urinary and radiological investigations. 
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METHODOLOGY 
 
A detailed history taking and clinical examination was done in 
patients with particular reference to hypertension. Relevant urine and  blood 
investigations were done. Fundus examination for hypertensive retinopathy 
and ultrasonogram were done in all patients.  
 
 1. Socio-demographic data: 
     Age                                  Sex                            Occupation/ Income    
    Family H/o hypertension (Father/Mother/Siblings) 
    Life style(Sedentary if physical activity < 3 METS) 
   Alcohol( Alcoholic defined > 2 drinks / day)                            
   Smoking (Smoker defined  > 5 cigarettes or beedis / day ) 
 
2. Clinical data: 
      BMI:77 
      Body Mass Index(BMI) = Weight (kg) / Height  (m) 2. 
Values        18.5 - 22.9 kg / m2 was taken as normal weight. 
                   23- 24.9 kg / m2 was taken as overweight. 
    ≥ 25 kg / m2 was taken as obesity. 
  Measurement of BP:  
 BP was measured as per JNC – 7 guidelines. Subjects were 
instructed not to take caffeine or smoking within 30 min preceding the 
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reading and were seated quietly for 5 min in a quiet room after 
emptying the bladder, with the arm bared and supported at the level of 
the heart and the back resting against a chair. A mercury manometer 
with appropriate cuffsize was used to measure the blood pressure. 
Korotkoff sounds phase I (appearance) was taken as systolic BP while 
phase V (disappearance) was taken as a measure of diastolic blood 
pressure. Two sets of BP readings were taken 30 min apart in both 
arms in sitting posture; if the pressures differ the arm with the higher 
pressure was taken. Lower limb BP was also taken in patients less 
than 40 years of age while BP recordings for postural hypotension 
were measured for those who aged more than 60 years. 
Other vital signs 
 General & Systemic examination 
 
3. Laboratory data: 
Urinalysis: 
Urine sample was collected for urine routine analysis which included 
sugar, protein, cytology and urinary sediments 
  
Urine spot PCR: 
Urine sample was collected to estimate protein creatinine ratio. Sulfo 
salicylic precipitation method was used for protein estimation. 
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Blood sugar: 
Blood sugar was estimated by Trinder’s (Glucose oxidase) method 
and read at 505/670 nm.  
 
Renal function test: 
 The blood urea in this study was estimated using DAM method 
(Diacetyl Monoxime). Serum creatinine was estimated using Modified 
Jaffe’s method. Electrolytes were measured by absorption 
spectrophotometry. 
 
Chest X – ray :                          
ECG:                   
USG Abdomen: 
 
ESTIMATION  OF  SERUM  CALCIUM :74 
 Arsenazo III Method: 
 
          The principle of this method is that calcium bind specifically with 
arsenazo III  at an acidic pH to form a blue – purple coloured compound.  
The intensity of the colour of the compound  is directly proportional to the 
amount of calcium present in  the sample. In the calcium estimation kit,   
there will be a standard sample with measured calcium of 10 mg/dl with 
which a standard stock solution(S) has to be prepared. The serum of  patient  
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is noted as test sample (T). A solution with distilled water is also prepared 
and branded as blank (B). Now the absorbance (Abs) of standard(S)  and 
test(T) are measured against the blank(B) by absorption spectrophotometry 
at 650 nm(Red) in room temperature within one hour and the readings to be 
noted. This method has a linearity upto 15 mg/dl. 
Serum Calcium (mg/dl) = [Abs of (T) / Abs of (S)] x10. 
 
ESTIMATION  OF  SERUM  PHOSPHORUS: 
Unreduced phosphomolybdate Method:74 
           The principle of this method  is that phosphate ions in acidic medium 
react with ammonium molybdate to form a phosphomolybdate complex.This 
complex has an absorbance in the ultraviolet range (340nm).The intensity of 
the colour of the complex  formed is directly proportional to the amount of 
inorganic phosphorus present  in the sample. In the phosphorus estimation 
kit, there will be a standard sample  with measured phosphorus of 5 mg/dl 
with which a standard stock      solution(S)  has to be prepared.The serum of  
patient  is noted as test sample (T). A solution with distilled water is also 
prepared and branded as blank (B). Now the absorbance (Abs) of 
standard(S) and test (T) are measured against the blank (B) by absorption 
spectrophotometry at   340nm in room temperature within one hour and the 
readings to be     noted. This method has a linearity upto 20 mg/dl. 
Serum Phosphorus (mg/dl) = [Abs of (T) / Abs of  (S)] x 5. 
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ESTIMATION  OF  SERUM  ALBUMIN:74 
Albumin BCG Method: 
The principle of this method is that albumin bind with the dye 
bromocresol green (BCG) in a buffered medium to form a green coloured 
complex. The intensity of the colour of the complex formed is directly 
proportional to the amount of albumin present in  the sample. In the albumin 
estimation kit, there will be a standard sample  with measured albumin of 
4g/dl with which a standard stock solution(S) has to be prepared. The serum 
of  patient  is noted as test sample (T). A solution with distilled water is also 
prepared and branded as blank (B). Now the absorbance (Abs) of 
standard(S) and test (T)  are measured against the blank(B)  by  absorption  
spectrophotometry at 628 nm(Red) and the readings to be noted. This 
method has a linearity upto 7 g/dl. 
Serum Albumin (g/dl) = [Abs of (T) / Abs of  (S)] x 4. 
 
CORRECTED SERUM CALCIUM LEVEL :74,75,76
= Serum Calcium(mg/dl) + { 0.8 [4.0 – Serum albumin (g/dl)] } 
In this study the correction was done for albumin using the above  formula 
and corrected serum calcium levels were obtained. 
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4. Statistical analysis: 
            Data was entered in Microsoft excel spread sheet and analysed 
statistically using SPSS software version 11.5. 
Results were considered significant if the ‘p’ value was below 0.05. 
 
The following tests were used for statistical analysis: 
1. Chi – square test. 
2. Student – t test. 
3. Analysis of variance(ANOVA). 
4. Pearson’s correlation. 
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RESULTS: 
 
 A total of 150 individuals were selected . They were divided into two 
groups, group A and group B. 
 Group A was the study group which included 100 newly detected 
essential hypertensive patients . Group B was the control group which 
included 50 normotensive individuals. 
 In Group A, 52 (52%) were males and 48(48%) were females and in 
Group B, 26(52%) were males and 24(48%) were females. 
 The mean age in group A was 55.52± 10.782 years and the mean age 
in group B was 52.06 ± 10.88 years. 
 Majority of hypertensives in the study group were asymptomatic 
(46%), and among the symptomatic individuals the commonest 
symptom was giddiness (24%) followed by headache (10%) . 
 In Group A, 70 (70%) were nonsmokers and 30 (30%) were smokers 
and in Group B,33(66%) were nonsmokers and 17 (34%) were 
smokers. In Group A, 69 (69%) were nonalcoholics and 31 (31%) 
were alcoholics and in Group B, 32(64%) were nonalcoholics and 18 
(36%) were alcoholics. 
 52% (52) patients in group A had a sedentary lifestyle. 
 The prevalence of family history of hypertension among hypertensive 
individuals was 37% (37). 
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 In group A, the prevalence of obesity as per India reworks obesity 
guidelines was 51% (51). 
 The mean systolic blood pressure of group A and group B were 
169.2800 ± 15.81847 mmHg and 111.7200 ± 6.88103mmHg while 
the mean diastolic blood pressure were 101.4000± 8.61054 mmHg  
and 71.1600 ±6.31280 mmHg respectively. 
 The mean total serum calcium and corrected serum calcium levels  in 
group A were 8.9160 ± 0.62529 mg/dl and 8.8263 ± 0.6525 mg/dl 
while the mean total serum calcium and corrected serum calcium 
levels  in group B were 9.7042± 0.79350mg/dl and 9.6550 ± 0.80053 
mg/dl  respectively. The calcium levels were significantly lowered in 
group A when compared with group B. 
 There was a negative correlation noted between the total and 
corrected serum calcium levels as against the systolic blood pressure. 
 There was no correlation noted between the total and corrected serum 
calcium levels as against the diastolic blood pressure. 
 There was no significant  difference in the total and corrected serum 
calcium levels  with  age , sex , BMI , life style , smoking , alcohol , 
family history of  hypertension in newly detected essential 
hypertensive patients. 
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AGE DISTRIBUTION BETWEEN GROUP A & GROUP B 
TABLE – 2: 
 
 GROUPS
 AGE  GROUP(years))) A B Total 
< 40 3 (3.0%) 2 (4.0%) 5 (3.3%)
41 – 50 33 (33.0%) 17 (34.0%) 50 (33.3%)
51 – 60 32 (32.0%) 17 (34.0%) 49 (32.7%)
61 – 70 21 (21.0%) 9 (18.0%) 30 (20.0%)
 
>70 11 (11.0%) 5 (10.0%) 16 (10.7%)
100 (100.0%) 50 (100.0%) 150 (100.0%) Total 
 
TABLE – 3: 
GROUP N Mean Age Std. Std. Error 
A 100 55.5200 10.78203 1.07820 
B 50 55.0600 10.85791 1.53554 
P value  betweeen groups was  0.988.   statistically not significant. 
 
There was no statistically significant difference noted in age 
distribution between  the groups A & B. (P > 0.05) 
 
SEX DISTRIBUTION BETWEEN GROUP A & GROUP B : 
TABLE – 4: 
GROUPSEX 
A B Total 
MALE 52 (52%) 26 (52%) 78 (52%)
FEMALE 48 (48%) 24 (48%) 72 (48%)
Total 100 (100%) 50 (100%) 150 (100%)
P value between groups is 1.0            statistically not significant. 
There was no statistically significant difference noted in the 
distribution of  sex  between the groups A & B. (P > 0.05). 
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DISTRIBUTION OF SMOKERS BETWEEN GROUPS A & B: 
TABLE – 5: 
 GROUP 
SMOKING A B Total 
NO 70 (70.0%) 33 (66.0%) 103 (68.7%) 
YES 30 (30.0%) 17 (34.0%) 47 (31.3%) 
TOTAL 100 (100.0%) 50 (100.0%) 150 (100.0%) 
 
P value between groups is 0.709           statistically not significant. 
There was no statistically significant difference noted between the 
groups A & B regarding smoking (P > 0.05). 
 
DISTRIBUTION OF ALCOHOLICS BETWEEN GROUPS A & B: 
TABLE – 6: 
ALCOHOL GROUP 
 A B Total 
NO 69 (69.0%) 32 (64.0%) 101 (67.3%) 
YES 31 (31.0%) 18 (36.0%) 49 (32.7%) 
TOTAL 100 (100.0%) 50 (100.0%) 150 (100.0%) 
 
P value between groups is 0.582           statistically not significant. 
There was no statistically significant difference noted between the 
groups A & B regarding alcohol. (P > 0.05). 
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LIFESTYLE DISTRIBUTION BETWEEN GROUPS A & B: 
TABLE – 7: 
GROUP LIFESTYLE 
A B Total 
SEDENTARY 52 (52.0%) 24 (48.0%) 76 (50.7%) 
NON SEDENTARY 48 (48.0%) 26 (52.0%) 74 (49.3%) 
TOTAL 100 (100.0%) 50 (100.0%) 150 (100.0%)
 
P value between groups is 0.730          statistically not significant. 
There was no statistically significant difference noted in lifestyle 
between the groups A & B. (P > 0.05). 
 
DISTRIBUTION  OF  FAMILY HISTORY OF HYPERTENSION  
BETWEEN GROUP A & GROUP  B: 
TABLE – 8: 
GROUP 
FAMILY HISTORY OF 
HYPERTENSION A B Total 
NO 63 (63.0%) 34 (68.0%) 97 (64.7%) 
YES 37 (37.0%) 16 (32.0%) 53 (35.3%) 
TOTAL 100 (100.0%) 50 (100.0%) 150 (100.0%)
P value between groups is 0.590         statistically not significant. 
There was no statistically significant difference noted in the 
distribution of family history between the groups A & B. (P > 0.05). 
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BMI 77 DISTRIBUTION BETWEEN GROUPS A & B: 
TABLE – 9: 
GROUP BMI (Kg / m2 ) 
A B Total 
BMI < 25 51 (51.0%) 23 (46.0%) 74 (49.3%) 
BMI > 25 49 (49.0%) 27 (54.0%) 76 (50.7%) 
TOTAL 100 (100.0%) 50 (100.0%) 150 (100.0%) 
 
P value between groups is 0.606         statistically not significant. 
There was no statistically significant difference noted in the 
distribution of BMI between the groups A & B. (P > 0.05). 
 
SYSTOLIC AND DIASTOLIC BLOOD PRESSURE  DISTRIBUTION 
BETWEEN GROUPS A & B: 
TABLE – 10: 
BLOOD 
PRESSURE 
(mmHg) 
 
GROUP 
N Mean 
Std. 
Deviation 
Std. Error 
Mean 
A 100 169.2800 15.81847 1.58185 SYSTOLIC 
B 50 111.7200 6.88103 .97312 
A 100 101.4000 8.61054 .86105 DIASTOLIC 
B 50 71.1600 6.31280 .89276 
P value between groups is 0.000  <  0.001   statistically significant. 
 
There was a statistically significant difference noted in the 
distribution of  blood pressure (systolic & diastolic) between the groups A & 
B. (P < 0.05). 
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DISTRIBUTION OF TOTAL SERUM CALCIUM LEVELS 
BETWEEN GROUP A AND GROUP B: 
TABLE – 11: 
GROUP N Mean Std. Std. Error 
A 100 8.9160 .62529 .06253 
TOTAL SERUM 
CALCIUM 
(mg/dl) 
B 50 9.7042 .79350 .11222 
P value between groups is 0.000  <  0.001   statistically significant. 
 
There was a statistically significant difference noted in the  total 
serum calcium levels between the groups A & B. (P < 0.05). 
 
DISTRIBUTION OF CORRECTED CALCIUM LEVELS BETWEEN 
GROUP A AND GROUP B: 
TABLE – 12: 
GROUP N Mean Std. Std. Error 
A 100 8.8263 .65250 .06525 
CORRECTED 
SERUM CALCIUM 
(mg/dl) 
B 50 9.6550 .80053 .11321 
P value between groups is 0.000  <  0.001   statistically significant. 
 
There was a statistically significant difference noted in the  corrected 
calcium levels between the groups A & B. (P < 0.05). 
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DISTRIBUTION OF SERUM PHOSPHORUS LEVELS BETWEEN 
GROUP A AND GROUP B: 
TABLE – 13: 
GROUP N Mean Std. Std. Error 
A 100 3.6829 .39549 .03955 
SERUM 
PHOSPHORUS 
(mg/dl) 
B 50 3.7866 .37802 .05346 
P value between groups is 0.127   not significant. 
 
There was no statistically significant difference noted in the  total 
serum phosphorus levels between the groups A &B(P < 0.05). 
 
DISTRIBUTION OF SERUM ALBUMIN LEVELS BETWEEN 
GROUP A AND GROUP B: 
TABLE – 14: 
GROUP N Mean 
Std. 
Deviation 
Std. Error 
Mean 
A 100 4.1169 .33042 .03304 
 
SERUM  
 ALBUMIN 
(g/dl) B 50 4.0780 .36100 .05105 
P value between groups is 0.511   not significant 
There was no statistically significant difference noted in the  total 
serum albumin  levels between the groups A &B(P < 0.05). 
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CORRELATION  BETWEEN SYSTOLIC BLOOD  PRESSURE AND 
TOTAL SERUM CALCIUM LEVELS IN GROUP A: 
TABLE – 15: 
 
GROUP A SYSTOLIC BP 
(mmHg) 
TOTAL 
 SERUM 
CALCIUM(mg/dl)
Pearson Correlation 1 -.466**
Sig. (2-tailed)  .000 
SYSTOLIC 
BP (mmHg) 
N 100 100 
Pearson Correlation -.466** 1 
Sig. (2-tailed) .000  
TOTAL  
SERUM  
 CALCIUM 
 (mg/dl) 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
The  correlation  co-efficient  was – 0.466 and p value  was 0.000 
which showed that the total serum calcium levels had a significant negative 
correlation with systolic blood pressure. 
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CORRELATION  BETWEEN SYSTOLIC BLOOD  PRESSURE AND 
CORRECTED CALCIUM LEVELS IN GROUP A: 
TABLE – 16: 
 
GROUP A SYSTOLIC BP
(mmHg) 
CORRECTED 
SERUM  
CALCIUM (mg/dl)
Pearson Correlation 1 -.526**
Sig. (2-tailed)  .000 
SYSTOLIC BP 
(mmHg) 
N 100 100 
Pearson Correlation -.526** 1 
Sig. (2-tailed) .000  
CORRECTED 
SERUM 
 CALCIUM  
(mg/dl) 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
 
The  correlation  co-efficient  was – 0.526 and p value  was 0.000 
which showed that the corrected serum calcium levels had a significant 
negative correlation with systolic blood pressure. 
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CORRELATION  BETWEEN DIASTOLIC BLOOD  PRESSURE 
AND TOTAL SERUM CALCIUM LEVELS IN GROUP A: 
TABLE – 17: 
 
GROUP A 
TOTAL SERUM  
CALCIUM 
(mg/dl) 
DIASTOLIC
 BP 
 (mmHg) 
Pearson Correlation 1 -.154**
Sig. (2-tailed)  .08 
TOTAL  
SERUM 
  CALCIUM 
 (mg/dl) 
N 100 100 
Pearson Correlation -.154** 1 
Sig. (2-tailed) 0.08  
DIASTOLIC 
 BP 
(mmHg) 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
 
The  correlation  co-efficient  was – 0.154 and p value  was 0.08 
which showed that the total serum calcium levels had no significant  
correlation with diastolic blood pressure. 
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CORRELATION  BETWEEN DIASTOLIC BLOOD  PRESSURE 
AND CORRECTED CALCIUM LEVELS IN GROUP A: 
TABLE – 18: 
 
GROUP A DIASTOLIC 
 BP 
 (mmHg) 
CORRECTED 
 SERUM 
 CALCIUM(mg/dl)
Pearson Correlation 1 -.142**
Sig. (2-tailed)  .102 
DIASTOLIC 
 BP 
(mmHg) 
N 100 100 
Pearson Correlation -.142** 1 
Sig. (2-tailed) .102  
CORRECTED 
SERUM 
 CALCIUM 
(mg/dl) 
N 100 100 
**. Correlation is significant at the 0.01 level (2-tailed). 
The  correlation  co-efficient  was – 0.142 and p value  was 0.102 
which showed that the corrected serum calcium levels had no significant  
correlation with diastolic blood pressure. 
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CORRELATION OF THE CALCIUM LEVELS WITH VARIOUS 
AGE GROUPS IN GROUP A 
TABLE – 19: 
GROUP A Age(Yrs) 
N Mean 
Std. 
Deviation Std. Error 
P VALUE
< 40 3 9.5467 .90118 .52030  
41 – 50 33 8.8891 .67116 .11683  
51 – 60 32 8.8794 .54102 .09564 .279 
61 – 70 21 8.8114 .61852 .13497  
>70 11 9.1309 .62815 .18939  
Total serum 
calcium 
(mg/dl) 
Total 100 8.9160 .62529 .06253  
< 40 3 9.1200 .91060 .52574  
41 – 50 33 8.7564 .67147 .11689  
51 – 60 32 8.7941 .56777 .10037 .621 
61 – 70 21 8.8129 .63399 .13835  
>70 11 9.0755 .83016 .25030  
Corrected 
serum 
calcium 
(mg/dl) 
Total 100 8.8263 .65250 .06525  
There was no statistically significant difference noted in the total and 
corrected serum calcium levels with different age groups in the study 
population, group A (P > 0.05). 
 
CORRELATION OF CALCIUM LEVELS WITH SEX IN        GROUP  
A: 
TABLE – 20: 
GROUP A SEX N Mean Std. Std. Error P 
Male 52 8.9506 .63474 .08802 .568 Total serum 
calcium (mg/dl) Female 48 8.8785 .61937 .08940  
Male 52 8.8744 .68507 .09500 .446 Corrected serum 
calcium (mg/dl) Female 48 8.7742 .61823 .08923  
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There was no statistically significant difference noted in the total and 
corrected serum calcium levels in relation to sex in group A (P > 0.05). 
CORRELATION OF THE CALCIUM LEVELS WITH SMOKING IN 
GROUP A: 
TABLE – 21: 
GROUP A 
SMOKING N Mean
Std. 
Deviation
Std. 
Error 
Mean 
P VALUE
YES 30 9.0600 .53540 .09775 .132 Total serum 
calcium(mg/dl) NO 70 8.8543 .65393 .07816  
YES 30 8.9883 .59871 .10931 .092 Corrected serum 
calcium (mg/dl) NO 70 8.7569 .66627 .07963  
There was no statistically significant difference noted in the total and 
corrected serum calcium levels  in group A in relation to smoking                   
(P > 0.05). 
CORRELATION OF THE CALCIUM LEVELS & ALCOHOL IN 
GROUP A: 
TABLE – 22: 
 
GROUP A 
ALCOHOL N Mean
Std. 
Deviation
Std. 
Error 
Mean 
P VALUE
YES 31 8.9829 .61192 .10990 .476 Total serum 
calcium(mg/dl) NO 69 8.8859 .63330 .07624  
YES 31 8.9577 .64731 .11626 .178 Corrected serum 
calcium(mg/dl) NO 69 8.7672 .65083 .07835  
There was no statistically significant difference noted in the total and 
corrected serum calcium levels  in group A in relation to alcohol. 
(P > 0.05). 
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CORRELATION OF THE CALCIUM LEVELS & LIFESTYLE IN 
GROUP A: 
TABLE – 23: 
GROUP A LIFE 
STYLE N Mean
Std. 
Deviation
Std. Error 
Mean 
P VALUE
S 52 9.0233 .62265 .08635 .074 Total serum 
calcium(mg/dl) NS 48 8.7998 .61347 .08855  
S 52 8.9765 .60509 .08391 .084 Corrected serum 
calcium(mg/dl) NS 48 8.6635 .66895 .09655  
There was no statistically significant difference noted in the total and 
corrected serum calcium levels in relation to lifestyle in group A 
(P > 0.05). 
CORRELATION OF THE CALCIUM LEVELS AND FAMILY 
HISTORY OF HYPERTENSION IN GROUP A: 
TABLE – 24: 
 
GROUP A 
FAMILY 
HISTORY N Mean
Std. 
Deviation
Std. 
Error 
Mean 
P 
VALUE
YES 37 8.9389 .63140 .10380 .780 Total serum 
calcium(mg/dl) NO 63 8.9025 .62637 .07891  
YES 37 8.8484 .66012 .10852 .797 Corrected serum 
calcium(mg/dl) NO 63 8.8133 .65296 .08227  
 
There was no statistically significant difference noted in the total and 
corrected serum calcium levels in relation to family H/o hypertension in 
group A (P > 0.05). 
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CORRELATION OF THE CALCIUM LEVELS AND  BMI  IN 
GROUP A: 
TABLE – 25: 
 
GROUP A BMI 
(Kg/m2) N Mean
Std. 
Deviation
Std. 
Error 
Mean 
P 
VALUE
< 25 51 8.8453 .63747 .08926 .251 Total serum 
calcium(mg/dl) > 25 49 8.9896 .61013 .08716  
< 25 51 8.7635 .72770 .10190 .329 Corrected serum 
calcium(mg/dl) > 25 49 8.8916 .56390 .08056  
 
There was no statistically significant difference noted in the                    
total and corrected serum calcium levels in relation to BMI in group A            
(P > 0.05). 
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DISCUSSION 
Systemic hypertension remains the most common, readily identifiable 
and reversible risk factor for myocardial infarction, stroke, heart failure, 
atrial fibrillation, aortic dissection and peripheral arterial disease.2  
 
Evidence is growing that calcium physiology is altered in essential 
hypertension, but whether this is a secondary association or a causal 
relationship is unresolved. Intracellular calcium ions are known to have 
direct effects on peripheral vascular tone and it has been reported in various 
trials that hypertensive persons have increased concentrations of 
intracellular free calcium that decrease to normal levels with 
antihypertensive treatment.67 
 
TOTAL AND CORRECTED SERUM CALCIUM LEVELS: 
Various epidemiological studies stated that the calcium status of 
humans with essential hypertension and genetic animal models of 
hypertension is characterized by low serum total and ionized calcium 
concentration, increased intracellular calcium, increased urinary calcium 
excretion, and   increased  parathyroid  hormone  (PTH) concentration.3-6,78 
 
This study used total serum calcium and corrected serum calcium, the 
latter is an alternative but not a substitute to serum ionised calcium. 
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 In this study the mean total serum calcium and corrected serum 
calcium levels  in group A(cases) were 8.9160 ± 0.62529 mg/dl and 8.8263 
± 0.6525 mg/dl while the mean total serum calcium and corrected serum 
calcium levels  in group B(controls) were 9.7042± 0.79350mg/dl and 9.6550 
± 0.80053 mg/dl  respectively. Statistical analysis revealed that the total and 
corrected serum calcium levels were significantly lowered in essential 
hypertensives when compared to their matched normotensive controls ( P < 
0.001 and P < 0.001 respectively).This observation is supported by some of 
the following studies. 
 
According to K. Sudhakar et al.,5 The mean total serum calcium levels 
were significantly (p<0.01) decreased in males and females in hypertensive 
group when compared with normotensive controls. In the first-degree 
relatives also the total serum calcium levels were significantly decreased           
(p <0.01) when compared with the controls. 
 
AR Folsom et al.,64  studied the serum calcium fractions in essential 
hypertensive and matched normotensive subjects. In their study he observed 
hypertensive subjects had lower mean serum levels of ultrafilterable calcium 
(p = 0.01), ionized calcium (p = 0.09), and complexed calcium (p= 0.04) and 
higher levels of protein-bound calcium   (p = 0.07). Calculated serum 
concentrations of complexed calcium was significantly lower in 
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hypertensive subjects (p = 0.04), while proteinbound calcium concentrations 
was higher (p = 0.07). Serum phosphorus and albumin concentrations, as 
well as estimated dietary calcium intake, were not different between the two 
groups. 
 
Fu Y, Wang S., et al.,65 in their study suggested that that the 
hypertensive group consistently demonstrated a significant decreased 
activity of ATPase studied, with significantly lower plasma calcium and 
higher cytosolic calcium levels when compared with those in normotensive 
group (P < 0.01 or P < 0.05, respectively). No significant differences were 
found in either plasma Mg2+ or intracellular Mg2+ level between the two 
groups. 
 
Strazzullo P et al.,66 studied several of the biochemical abnormalities 
of calcium metabolism and were able to detect a significant reduction in 
total serum calcium levels in hypertensive subjects, although unable to 
detect a significant reduction in serum ionized calcium levels.This study 
also reported total and fractional urinary calcium excretion were elevated in 
subjects with essential hypertension. 
 
Erne P, Bolli P., et al.,67 in their study on “correlation of platelet 
calcium with blood pressure: effect of antihypertensive therapy” reported a 
decrease in the serum total calcium concentration in essential hypertensive 
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patients. Touyz, R.M.,et al., 4 also reported a decrease in the serum total 
calcium concentration in essential hypertensive patients. 
 
Some investigators; McCarron DA., 68 and Resnick LM, Laragh JH.,et 
al.,69 also noted that, compared with normotensive subjects,essential 
hypertensive subjects had lower serum ionized calcium concentrations even 
when total calcium levels were similar.  
 
Wright GL, Rankin GO.,79  in their study on concentrations of ionic 
and total calcium in plasma of  four models of  hypertension  noted a  lower 
serum ionized and total serum calcium concentrations in spontaneously 
hypertensive rats(SHR). 
 
Several other investigators have reported positive associations 
between blood pressure levels and concentrations of serum total calcium 
which is in contrast with the present study. Harlan WR., et al., 80 , Rolf 
Jorde.,et al., 81 and Kesteloot H.,et al., 82 observed a direct correlation 
between serum total calcium concentrations and arterial pressure. This 
seemingly paradoxical observation is likely secondary to a failure of the 
investigators to correct for the hemoconcentration that attends human 
hypertension.83  This failure results in an artifactual increase in total calcium 
values because of an increase in serum protein (albumin) concentration, the 
fraction to which most calcium is bound. 
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CORRELATION OF TOTAL AND CORRECTED SERUM 
CALCIUM LEVELS WITH SYSTOLIC BLOOD PRESSURE: 
 
 In this present study  a correlation between calcium levels and systolic 
blood pressure was attempted and found that the total and corrected serum 
calcium levels had a significant negative correlation with systolic blood 
pressure (P < 0.01and P < 0.01 respectively). 
 
Ottar Hals 84 in his study found that  pretreatment systolic blood 
pressure was inversely correlated to serum ionized calcium (r = — 0.44,and  
p = 0.05). The result in this study supports our study. Also according to 
Morris, C.D.et al., 84 and Christina Martinez 85, there was a clear inverse 
relationship between calcium and both the prevalence of hypertension and 
the level of blood pressure. 
 
AR Folsom et al., 64 studied the serum calcium fractions in essential 
hypertensive and matched normotensive subjects. In his study, there was no 
significant correlation between individual systolic blood pressure levels and 
the serum calcium fractions. 
 
Phillips AN.,et al., 87 in their  “The British Regional Heart Study” 
found a  significant positive correlation between serum calcium and both 
systolic and diastolic blood pressure after adjusting for age. This association 
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was diminished after adjustment for serum albumin, but remained 
significant. This association disappeared after adjustment for serum 
globulins and haematocrit in addition to age and serum albumin. Thus, these 
factors appear to mediate the weak association between serum calcium and 
both systolic and diastolic blood pressure. There does not appear to be an 
independent relationship between serum calcium and blood pressure. 
 
 Some works done by Staessen  J, Sartor F,et al., 88  Jorde.,et al., 81 and  
Kesteloot H.,et al., 82 showed that serum total calcium was independently  
and  positively  correlated with systolic pressure in essential hypertensives. 
CORRELATION OF TOTAL AND CORRECTED SERUM 
CALCIUM LEVELS WITH DIASTOLIC BLOOD PRESSURE: 
In our study we also attempted a correlation between the calcium 
levels and diastolic blood pressure  and  found  that there was no correlation 
between the total and corrected serum calcium levels and diastolic blood 
pressure (P >0.05and P > 0.05 respectively). 
 
In his study on  ‘the serum calcium fractions in essential hypertensive  
and  matched  normotensive subjects’ AR Folsom et al.,64 also noticed that 
there was no significant correlations between the serum calcium fractions 
and diastolic blood pressure levels. 
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Jorde.,et al., 81and Kesteloot H, Geboers J.,82 showed a significant 
positive correlation between total serum calcium and diastolic blood 
pressure.  Kesteloot H, Joossens JV.,89 showed that serum calcium correlated 
positively with systolic and diastolic blood pressure in men, but only with 
diastolic blood pressure in women. 
 
CORRELATION OF TOTAL AND CORRECTED SERUM 
CALCIUM LEVELS WITH VARIOUS SUBSETS OF STUDY 
GROUP(ESSENTIAL HYPERTENSIVE GROUP): 
Our study also had an objective of comparing total and corrected 
serum calcium levels with various subsets of essential hypertensive 
population like age, sex, smoking,  alcohol, family history of hypertension, 
lifestyle and BMI. After statistical analysis, it was  revealed that there was 
no significant difference between the calcium levels in the  above mentioned 
parameters( P > 0.05). 
 
Jorde.,et al., 81 , in his study noticed that there was a significant 
decrease in serum calcium with increasing age in men while a significant 
increase in women. According to AR Folsom et al.,64 and  Staessen  J, Sartor 
F,et al., 88  serum total calcium  was similar in both the  sexes and no 
significant difference noted. 
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According to C Brot.,et al., 90 noted that there was no difference in 
serum ionized calcium between smokers and non-smokers in their study. 
J. Sundsfjord., R. Jorde., et al., 91 in an observation of tromso study, showed 
a positive association of serum calcium with body mass index (BMI) in both 
sexes that persisted after correcting for other variables in a multiple 
regression model. Physical activity(lifestyle)  had no significant association 
with serum calcium.In females alcohol consumption was negatively, and 
cigarette smoking was positively associated with serum calcium. 
 
K. Sudhakar et al.,5  found that the first-degree relatives of essential 
hypertensive patients  had  a significantly decreased  ( p<0.01) total serum 
calcium levels when compared with the controls. 
 
LIMITATIONS OF THE STUDY: 
1. The sample size was small. 
2. This being a cross sectional study follow up was not done. 
3. Serum ionised calcium, cytosolic calcium, urinary calcium, serum 
parathormone levels, serum renin levels, and serum Vit D3 levels 
were not measured due to constraints. 
4. Calcium supplementation was not attempted in the patients due to 
ethical reasons. 
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SUMMARY 
 
 The present study aimed at comparing the total and corrected serum 
calcium levels in newly detected essential hypertensive patients with 
matched normotensive controls. It also aimed at correlating the total and 
corrected serum calcium levels with systolic and diastolic blood pressure in 
newly detected essential hypertensive patients. With rigid criteria 150 
individuals, 100 essential hypertensives cases and 50 normotensive controls 
were selected and enrolled in the study. 
 
 The total and corrected serum calcium levels were found to be 
significantly lowered in cases when compared to controls. Also a significant 
negative correlation between the calcium levels and systolic blood pressure 
was noted while there was no correlation noted with the diastolic blood 
pressure in the cases. This study also noted that there is     no significant 
difference in both the calcium levels with age, sex, BMI, lifestyle, smoking, 
alcohol, family H/o hypertension in newly detected essential hypertensive 
patients. 
 
  This study recommends calcium intake in essential hypertensives 
mainly in the form of fruits and non-fatty dairy products similar to DASH 
trials. As calcium supplements may rarely raise blood pressure and increase 
the risk of kidney stones, further larger studies with randomised controlled 
trials are necessary to support the view on calcium supplementation. 
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CONCLUSION 
 
1. The total and corrected serum calcium levels are significantly lowered 
in newly detected essential hypertensive patients when compared to 
normotensive controls. 
2. The total and corrected serum calcium levels have a significant 
negative correlation with the level of systolic blood pressure in newly 
detected essential hypertensive patients. 
3. The total and corrected serum calcium levels have no significant 
correlation with the diastolic blood pressure in newly detected 
essential hypertensive patients. 
4. The total and corrected serum calcium levels showed  no  significant  
difference  with  age , sex , BMI , life style , smoking , alcohol 
,family history of  hypertension in newly detected essential 
hypertensive patients. 
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DEPARTMENT OF MEDICINE 
 
             Govt Kilpauk Medical College &  Hospital, Chennai – 10. 
 
PROFORMA 
ESTIMATION OF SERUM  CALCIUM LEVELS IN NEWLY 
DETECTED ESSENTIAL HYPERTENSION PATIENTS 
 
S.No.                                                   Reg. No. (OP/IP) 
Name:                 Age/Sex 
Address: 
 
Occupation/Income:                                                      
Presenting Complaints: 
Headache                        Vomiting                              Giddiness                                     
Breathlessness                Oliguria                                Palpitation  
Facial puffiness              Swollen Limb                       Epistaxis                                       
Syncope                          Chest pain                            Anorexia 
Easy fatigability              Blurring of vision                 Hiccough 
Polyuria                           Nocturia                               Polydipsia 
Muscle spasms                Convulsions                         Paresthesia 
Abdominal pain               Sweating                              Tremors 
Impotence                        Snoring                               Constipation 
Weight Gain/Weight Loss       Cold Intolerance   
Change in Voice       Menstrual Irregularities 
Emotional disturbances                            Others                        
PAST HISTORY 
SHT                                    DM                            Angina/MI/IHD/CCF    
STROKE/TIA                      PVD                           RENAL DISORDERS                      
BLOOD TRANSFUSION      THYROID SURGERY     Others 
 
FAMILY HISTORY 
HYPERTENSION     (Father/Mother/Siblings )     DM                   IHD 
 
PERSONAL HISTORY 
DIET : Veg/Non-veg LIFE STYLE: Sedentary/Non-sedentary 
Addiction: Tobacco Chewing/Smoking /Drug Abuse 
Alcohol-Occasional/Daily/Moderate/Heavy  
Menstrual History 
H/o Drug intake 
 
GENERAL EXAMINATION 
HEIGHT(m):                          WEIGHT(Kg):                        BMI(Kg/m2) : 
Pallor                     Cyanosis                Clubbing                   Icterus               
Pedal edema           GLA                       JVP 
Markers  of  Atherosclerosis 
Features of  Hypothyroidism/Acromegaly/Cushing’s syndrome  
FUNDUS EXAMINATION: 
 
VITAL SIGNS 
PR :                                  RR :                               Temperature (F): 
 Blood pressure:     RUL:  I -                              II - 
           (mmHg)       LUL:  I -                              II - 
                                    
SYSTEMIC EXAMINATION: 
C. V. S:         S1-                              S2-                Murmur: 
 
R. S.   :         NVBS                                     Added sounds: 
P/A    :         Organomegaly               Renal bruit/ Renal angle tenderness 
C. N. S:  
 
INVESTIGATIONS: 
 
URINE  R/E:     Albumin-               Sugar-                 Deposits- 
CBC             :     Hb (g/dl)-          TLC/mm3-             DC-                 
ESR(mm) - 
Urine Spot PCR:  
                      Protein(mg%) -               Creatine(mg%) -                      Ratio: 
BLOOD SUGAR (mg/dl)               : 
BLOOD UREA  (mg/dl)                 : 
SERUM CREATININE (mg/dl)      : 
SERUM SODIUM     (mEq/L)        : 
SERUM POTASSIUM    (mEq/L)    :     
SERUM CALCIUM (mg/dl)             : 
SERUM PHOSPHORUS (mg/dl)      :  
SERUM ALBUMIN  (g/dl)                :           
CORRECTED CALCIUM LEVEL (mg/dl) : 
              
CHEST X-RAY:                               ELECTROCARDIOGRAM: 
 
 
ABDOMINAL ULTRASONOGRAM: 
 
  
MASTER CHART 
ESSENTIAL HYPERTENSION PATIENTS (STUDY GROUP/ GROUP - A )  
          BLOOD 
PRESSURE(mmHg ) 
S.No         NAME
Op/Ip 
No Age Sex Symptoms Smoking Alcohol
Life 
style 
Family 
H/O 
BMI 
(Kg/m2) 
BMI 
Group Systolic Diastolic
Blood 
Urea 
(mg/dl) 
Serum 
Creatinine 
(mg/dl) 
USG 
Abd 
T. Sr. 
Calcium 
(mg/dl) 
Serum 
Phos 
(mg/dl) 
Serum 
Albumin 
(g/dl) 
C  Sr. 
Calcium   
(mg/dl)    
1                     Mr.Eesan 316 52 M H Y N S N 26.88 2 150 94 25 0.8 N 9.26 2.8 4.2 9.1
2                     Mrs.Lakshmi 333 48 F H , G N N NS Y 27.94 2 144 96 24 0.4 N 9.38 3.6 4.4 9.06
3                     Mrs.Chakkamma 342 62 F  - N N NS N 21.8 1 184 96 27 0.7 N 8.02 3.2 4.2 7.86
4                     Mr.Purusothaman 352 45 M  - Y N S N 22.79 1 156 94 24 0.6 F 9.42 3.2 3.8 9.58
5                     Mrs.Ellammal 405 45 F H N N NS N 21.09 1 182 98 26 0.6 N 9 3 4.5 8.6
6                     Mrs.Pattammal 412 65 F G N N S N 20.3 1 164 102 27 0.7 N 8.15 3.6 3.5 8.55
7                     Mr.Ramalingam 414 53 M  - Y N S N 20.76 1 148 90 36 1.1 N 9.7 4.1 4.4 9.38
8 Mrs.Nagammal                    506 56 F - N N S Y 27.57 2 170 106 19 1 F 8.9 4 3.8 9.06
9                     Mr.Ramakrishnan 513 43 M  - Y N NS N 21.99 1 164 106 27 0.8 N 8.32 3.2 4 8.32
10 Mr.Mohamed Safi 520 54 M  - N N NS N 27.95 2 162 90 26 0.6 N 8.24 3.6 4 8.24 
11                     Mr.Rajan 522 52 M  - N Y S Y 20.31 1 194 114 28 0.8 N 8.42 3.5 4.5 8.02
12                     Mr.Narasaiah 585 74 M EF N Y S N 20.56 1 182 112 32 1 N 8.12 3.9 4.8 7.48
13                     Mr.Parthasarathy 586 65 M G Y Y NS N 23.18 1 158 96 28 0.8 N 9.05 3.5 4.4 8.73
14                     Mrs.Suseela 636 56 F G N N NS Y 19.62 1 186 102 24 0.6 N 8.3 4.2 4.2 8.46
15                     Mr.C.Pandurangan 639 67 M  - Y N NS N 30.14 2 186 104 22 0.7 N 8.06 3.8 4.2 7.9
16                     Mr.Navaneethan 642 45 M H N Y NS Y 28.33 2 160 98 25 0.5 N 8.3 3.6 3.8 8.46
17 Mrs.Shanthi                     644 58 F - N N NS Y 27.12 2 174 108 20 0.8 N 9 3.9 4.5 8.6
18                     Mrs.Thilagavathy 654 54 F  - N N S N 20.58 1 182 96 32 0.8 F 9.48 3.8 4.3 9.24
19                     Mrs.Manohari 663 45 F H N N NS N 19.06 1 178 102 22 0.6 N 8.52 2.9 4 8.52
20                     Mrs.Regina 664 46 F G N N S N 20.8 1 160 110 27 0.7 N 9.14 3.7 4.1 9.06
21                     Mrs.Rajammal 665 75 F G N N NS N 23.28 1 172 92 32 0.7 N 10 3.8 3.8 10.12
22                     Mrs.Devaki 668 55 F G N N S N 26.77 2 174 102 24 0.6 N 8.56 3.7 4.2 8.4
23                     Mr.Lenin 669 55 M  - Y Y S N 20.21 1 140 92 24 0.6 N 8.5 3.5 3.5 8.9
24                     Mrs.Kaliyammal 674 56 F G N N NS N 21.05 1 166 96 27 0.9 N 8.36 4 4.4 8.04
25                     Mrs.Geetha 682 41 F  - N N NS N 19.6 1 176 102 26 0.6 N 8.44 3.4 4.4 8.12
 
MASTER CHART 
ESSENTIAL HYPERTENSION PATIENTS (STUDY GROUP/ GROUP - A )  
 BLOOD 
PRESSURE(mmHg ) 
S.No         NAME
Op/Ip 
No Age Sex Symptoms Smoking Alcohol
Life 
style 
Family 
H/O 
BMI 
(Kg/m2) 
BMI 
Group Systolic Diastolic
Blood 
Urea 
(mg/dl) 
Serum 
Creatinine 
(mg/dl) 
USG 
Abd 
T. Sr. 
Calcium 
(mg/dl) 
Serum 
Phos 
(mg/dl) 
Serum 
Albumin 
(g/dl) 
C  Sr. 
Calcium   
(mg/dl)    
26                     Mr.Meeran 688 49 M  - Y Y NS Y 20.92 1 168 98 27 0.6 N 8.8 3.9 4.1 8.72
27                     Mrs.Kumutha 689 64 F  - N N NS Y 20.3 1 196 124 32 0.8 N 8.1 3.9 4.2 7.94
28                     Mr.Sriram 694 73 M EF N N NS N 21.27 1 152 98 26 0.8 N 8.32 3.6 4.2 8.16
28 Mr.Kathiresan  704 59 M  - Y N NS Y 22.22 1 172 106 22 0.7 N 8.72 2.9 4.5 8.32 
30                     Mrs.Parimala 826 55 F  - N N S N 25.36 2 152 98 26 0.9 N 9.02 2.9 3.9 9.1
31 Mrs.Mala 827 48 F G , H N N S N 27.96 2 172 100 26 0.5 F 9 2.9 3.7 9.24 
32                     Mrs.Jamunamma 828 45 F  - N N S N 28.13 2 176 102 27 0.8 N 8.32 4 4.2 8.16
33 Mr.Ajesh                    829 57 M - Y Y S Y 26.77 2 150 92 27 0.6 N 8.5 4.1 3.5 8.9
34                     Mrs.Viruthambal 830 53 F  - N N S N 28.12 2 172 98 18 0.7 N 8.66 3.6 4 8.66
35 Mr.Lingam 839 51 M H , G Y N NS N 21.32 1 154 92 29 0.9 N 9.1 3.7 4 9.1 
36                     Mrs.Annammal 840 65 F G N N S Y 26.71 2 148 94 18 0.6 N 9.29 4.2 3.5 9.69
37                     Mrs.Alamelu 849 65 F  - N N NS N 32.09 2 194 116 27 0.8 N 8.37 3.7 4.1 8.29
38                     Mrs.Sarojamma 866 72 F  - N N NS Y 26.95 2 174 90 28 0.9 N 8.66 3.1 4 8.66
39                     Mrs.Mumtaj 870 64 F  - N N S N 27.82 2 162 100 36 1.1 N 8.5 3.9 3.8 8.66
40 Mr.Ravi                    877 48 M - N Y S N 26.18 2 170 90 18 0.9 N 8.45 3.4 4 8.45
41                     Mr.R.Madavan 878 58 M  - Y Y NS Y 21.01 1 170 96 22 0.6 N 9.21 3.9 4.2 9.05
42 Mr.Manjunathan 884 43 M H , S N Y S Y 28.12 2 156 98 34 0.9 N 8.66 3.8 3.7 8.9 
43 Mr.Masilamani 885 45 M G , H Y Y S Y 19.35 1 162 96 29 0.6 N 8.5 3.6 3.8 8.66 
44                     Mr.C.Ramanujam 888 55 M G N Y NS N 27.33 2 174 108 18 0.6 N 8.24 3.3 3.9 8.32
45 Mr.Magudeswaran 890 76 M                 H Y N S Y 28.67 2 150 90 28 0.8 N 9.44 3.2 3.8 9.6
46                     Mr.Loganathan 917 65 M  - N Y NS Y 26.24 2 164 92 27 0.7 N 8.98 3.6 4 8.98
47 Mrs. Suguna 919 52 F H , G N N S N 27.69 2 170 118 24 0.8 N 8.26 4.1 4.2 8.1 
48                     Mrs.Therasa 921 58 F - N N NS Y 26.87 2 162 92 26 0.8 F 9 3.4 3.7 9.24
49                     Mrs.Babyamma 940 65 F G N N S N 30.45 2 182 96 20 0.7 N 8.06 3.6 3.6 8.38
50                     Mrs.Malini 945 48 F H N N S N 21.87 1 206 126 27 0.7 N 8.06 3.2 4.5 7.76
 
MASTER CHART 
ESSENTIAL HYPERTENSION PATIENTS (STUDY GROUP/ GROUP - A ) 
 BLOOD 
PRESSURE(mmHg ) 
S.No         NAME
Op/Ip 
No Age Sex Symptoms Smoking Alcohol
Life 
style 
Family 
H/O 
BMI 
(Kg/m2) 
BMI 
Group Systolic Diastolic
Blood 
Urea 
(mg/dl) 
Serum 
Creatinine 
(mg/dl) 
USG 
Abd 
T. Sr. 
Calcium 
(mg/dl) 
Serum 
Phos 
(mg/dl) 
Serum 
Albumin 
(g/dl) 
C  Sr. 
Calcium   
(mg/dl)    
51                     Mr.Deivasigamani 950 68 M N N N NS Y 21.98 1 190 112 22 0.7 N 8.02 3.9 4.1 7.94
52                     Mr.Babu 953 43 M  - N N NS N 20.07 1 186 116 17 0.7 N 7.82 3.8 4.2 7.66
53 Mrs.Kasthuri                    957 43 F H N N S N 20.95 1 174 98 32 1 N 8.5 3.7 4.2 8.34
54                     Mr.S.Rajendran 960 61 M H Y Y NS Y 21.12 1 160 98 28 0.7 N 9.72 3.6 3.5 10.12
55                     Mr.Jeyakumar 969 45 M  - N Y S Y 19.14 1 174 98 26 0.8 N 8.4 4 3.8 8.56
56                     Mrs.Saradha 978 70 F G ,H N N NS N 20.31 1 164 96 33 0.8 N 9.19 3.8 3.9 9.27
57                     Mrs.Kuppu 988 45 F G N N S N 19.38 1 174 106 29 1.1 N 8.51 3.3 4.1 8.43
58                     Mrs.Visalakshi 990 72 F G N N S N 27.55 2 156 92 22 0.8 N 9.83 2.9 4.5 9.43
59                     Mr.Rajiv 994 42 M  - Y Y NS N 28.52 2 144 92 17 0.8 N 9.46 3.6 4 9.46
60                     Mr.Palanivel 1004 67 M G Y Y NS N 27.33 2 158 96 30 0.6 N 8.96 3.4 3.7 9.18
61 Mrs.Murugamma                     1056 45 F - N N S N 25.95 2 148 96 18 0.8 N 9.8 3.9 4.5 9.4
62                     Mrs.Renugadevi 1599 36 F G N N S Y 24.12 1 152 106 26 0.7 N 10.42 4.0 4.4 10.1
63 Mr.Yuvaraj                   1613 39 M - Y N NS Y 28.12 2 186 108 29 0.9 N 8.62 3.9 4.4 8.3
64                     Mr.Dharmaiah 1646 73 M G Y Y S N 21.45 1 166 92 32 1 N 9.62 3.4 3.5 10.02
65                     Mrs.Kala 1653 52 F  - N N NS N 20.42 1 184 108 18 0.8 N 8.64 4.3 4.5 8.24
66                     Mrs.Arokiyamary 1655 76 F  - N N S N 30 2 194 102 28 1 N 8.78 3.3 4.4 8.46
67                     Mrs.Vembu 1667 68 F G N N S Y 27.2 2 166 116 21 0.7 N 8.36 3.8 3.5 8.76
68                     Mr.Selvam 1671 54 M G Y Y NS Y 28.04 2 166 98 26 0.9 N 9.03 3.6 3.9 9.11
69 Mr.Sampath                   1679 52 M - Y Y NS N 20.76 1 194 112 30 0.7 N 8.12 3.4 4 8.12
70                     Mr.Johnson 1686 64 M  - Y N S Y 26.88 2 166 96 24 0.7 N 9.32 3.9 4.2 9.16
71                     Mr.Chandran 1687 47 M  - Y N NS Y 29.75 2 174 104 24 0.8 N 8.91 2.9 4.2 8.75
72 Mrs.Maheswari                     1691 42 F - N N S N 21.37 1 162 96 21 0.8 N 9.37 4.1 4 9.37
73                     Mrs.Fathima 1958 55 F  - N N S Y 20.99 1 164 98 20 0.7 N 8.66 4.2 4 8.66
74 Mr.Rajendran 1968 45 M G , P N Y NS Y 26.91 2 142 92 19 0.7 N 10.5 3.7 4.6 10.02 
75 Mr.Abraham 1970 46 M H , S N N S Y 28.69 2 158 96 22 0.8 F 10.48 3.9 4.36 10.19 
 
MASTER CHART 
ESSENTIAL HYPERTENSION PATIENTS (STUDY GROUP/ GROUP - A ) 
 BLOOD 
PRESSURE(mmHg ) 
S.No        NAME
Op/Ip 
No Age Sex Symptoms Smoking Alcohol
Life 
style 
Family 
H/O 
BMI 
(Kg/m2) 
BMI 
Group Systolic Diastolic
Blood 
Urea 
(mg/dl) 
Serum 
Creatinine 
(mg/dl) 
USG 
Abd 
T. Sr. 
Calcium 
(mg/dl) 
Serum 
Phos 
(mg/dl) 
Serum 
Albumin 
(g/dl) 
C  Sr. 
Calcium   
(mg/dl)    
76 Mrs.Rambika                    1972 55 F H N N S N 27.7 2 150 94 20 0.7 N 10.23 3.5 4.33 9.96
77 Mr.Manoharan                     1975 36 M - Y Y S N 27.71 2 150 108 29 0.9 N 9.6 3.7 4.8 8.96
78                     Mrs.Panchali 14849 65 F G N N NS N 25.51 2 188 108 26 0.8 N 9.8 3.9 4.4 9.48
79 Mrs.Baby                    21468 42 F G , H N N S Y 28.12 2 146 104 18 0.7 N 9.52 4.1 4.6 9.04
80 Mrs.Ramani                    22523 55 F - N N S N 34.31 2 174 108 27 0.9 N 8.9 3.9 4 8.9
81 Mrs.Kotteswari 24141 55 F G , S N N S N 31.11 2 170 104 26 1.1 N 8.72 3.8 4.4 8.4 
82 Mrs.Padmavathy 24222 50 F H  , G N N NS N 23.98 1 204 122 26 1 N 7.8 4.1 4.3 7.56 
83 Mr.S.Durai                   24270 54 M EF Y Y S N 19.66 1 194 116 20 0.1 N 10.13 3.9 4.33 9.87
84 Mrs.Amudha 24411 44 F  G  , F N N NS Y 34.58 2 196 120 22 0.9 F 8.5 3.9 4.6 8.02 
85 Mr.Kannaiah                    24423 85 M - N N S N 19.42 1 152 92 32 0.9 N 8.95 3.4 4.2 8.79
86 Mr.M.Durai 24441 60 M H  , G Y Y NS Y 27.48 2 174 108 20 0.7 N 8.3 4 4.8 7.66 
87 Mr.Mahadevan                   24465 65 M G Y N S N 24.11 1 150 96 30 1 N 8.79 3.3 4.3 8.55
88                     Mr.Shankar 24502 61 M G N N NS N 27.79 2 158 98 24 1 N 9.66 4 4.14 9.55
89 Mr.Raju                   24532 55 M G N Y S N 23.62 1 190 122 24 1.1 N 9.01 3.9 3.54 9.38
90 Mr.Karunakaran                    24533 50 M - Y Y S N 21.75 1 186 106 24 0.9 N 9.55 4.2 4.11 9.46
91 Mr.Raja Bagadhur 24615 75 M G , S N Y S N 22.14 1 152 92 23 1.1 N 9.04 4.1 3.51 9.43 
92                     Mr.Munusamy 24696 55 M  - N Y NS N 26.42 2 152 92 34 1.1 N 9.46 3.9 4.24 9.27
93                     Mrs.Angamma 24737 41 F H N N NS N 22.22 1 178 108 24 0.8 N 9.25 4.0 4.04 9.25
94 Mrs.Jeyalakshmi                   24802 63 F G N N S Y 26.99 2 208 96 18 0.8 N 9.16 3.6 4.4 8.84
95 Mr.Srinivasan                   24820 56 M G N N S N 20.43 1 168 100 40 1.1 N 9.51 3.3 3.87 9.61
96                     Mr.Kannan 25126 65 M  - Y Y NS N 29 2 164 102 22 0.8 N 9.48 4.5 4.3 9.24
97 Mrs.Jayanabee                    25143 80 F - N N S N 20.41 1 152 102 24 1.1 N 9.68 4.6 4 9.68
98 Mr.Veerasamy                  25365 45 M G N N NS Y 23.66 1 184 102 18 0.7 N 8.3 3.4 4.9 7.58
99                     Mr.Santhanam 40201 49 M G , E Y Y NS Y 21.64 1 170 112 24 0.9 N 9.61 3.1 4.22 9.43
100                     Mr.Narayanan 40884 41 M  N Y NS Y 20.76 1 196 96 29 0.9 N 8.75 4.7 3.9 8.83
 
MASTER CHART 
NORMOTENSIVE INDIVIDUALS (CONTROL GROUP/ GROUP - B ) 
 BLOOD 
PRESSURE(mmHg ) 
S.No        NAME
Op/Ip 
No Age Sex Smoking Alcohol
Life 
style 
Family 
H/O 
BMI 
(Kg/m2) 
BMI 
GROUP Systolic Diastolic
Blood 
Urea  
(mg/dl) 
Serum 
Creatinine 
(mg/dl) 
USG 
Abd 
T . Sr. 
Calcium 
(mg/dl) 
Serum 
Phos 
(mg/dl) 
Serum 
Albumin 
(g/dl) 
C. Sr. 
Calcium  
(mg/dl)    
1 Mrs.Parimala                   2045 72 F N N S N 28.62 2 110 70 27 0.8 N 8.34 3.8 4.5 7.94
2 Mr.Shanmugam                  2789 46 M Y N NS Y 20.21 1 122 76 22 1.1 N 10.6 3.5 3.8 10.76
3 Mrs.Krishnaveni                  2980 47 F N N NS N 30.45 2 116 80 24 0.9 N 8.7 3.9 4.5 8.3
4 Mr.Sivakumar                  3065 62 M Y N NS N 20.64 1 112 72 29 0.7 N 11.74 3.5 4.3 11.5
5 Mrs.Pachaimmal                  3228 56 F N N NS N 27.82 2 110 72 36 1 N 9.72 3.6 3.7 9.96
6 Mr.Kuppusamy                  4667 68 M Y Y S N 20.3 1 100 64 22 0.9 N 10.08 3.8 4.3 9.84
7 Mr.S.Madavan                  4779 42 M N Y NS Y 29.75 2 106 60 30 0.1 N 8.08 2.9 3.6 8.4
8 Mrs.Devi                  5039 42 F N N NS N 19.35 1 120 76 28 0.8 F 10.92 3.2 4 10.92
9 Mrs.Thangamma                  5057 66 F N N NS N 28.13 2 110 72 36 0.7 N 9.88 3.2 4.2 9.72
10 Mr.Murugappan                  6234 58 M Y Y NS N 28.12 2 120 76 28 0.8 F 9.12 3.5 4.5 8.72
11 Mrs.Andalamma                   6785 58 F N N S Y 21.37 1 106 60 30 0.1 N 9.68 3.8 4.1 9.52
12 Mrs.Rashida                   7889 58 F N N S Y 28.12 2 100 64 22 0.9 N 9.46 4.1 4.1 9.38
13                    Mrs.Kanagavalli 10112 57 F N N NS N 27.96 2 106 60 30 0.1 N 9.54 3.8 4.4 9.22
14 Mr.Krishnamoorthy 12354 44 M                N Y NS N 22.22 1 120 76 28 0.8 N 10.9 3.9 3.9 10.82
15 Mr.Ramalingam                 12387 62 M Y Y S Y 23.18 1 110 70 27 0.8 N 9.46 3.4 5.2 8.5
16 Mrs.Shanthi                   13657 46 F N N S Y 27.55 2 112 72 29 0.7 N 10.96 3.0 4.4 10.64
17 Mr.Mohammed                 13678 56 M Y Y NS N 20.76 1 112 70 23 0.6 N 9.7 3.9 3.9 9.78
18 Mrs.Mary                   13998 64 F N N S N 26.88 2 106 74 28 0.7 N 9.94 3.9 4.3 9.67
19 Mr.Raman                 14367 59 M Y Y S Y 20.95 1 122 76 22 1.1 N 9.94 4.0 3.9 10.02
20 Mr.Murali                 14546 48 M Y N S Y 20.07 1 120 78 26 0.8 N 9.7 3.9 4.1 9.62
21 Mr.Mariappan                 14876 46 M Y N NS Y 27.69 2 116 80 24 0.9 N 10.36 3.8 4.2 10.2
22 Mrs.Indirani                   15243 42 F N N S N 26.77 2 100 64 22 0.9 N 9 4.1 3.5 9.4
23 Mr.Anwar basha                 15678 74 M N Y S Y 28.33 2 110 72 36 1 N 9.92 4.3 4 9.92
24 Mrs.Amudha                   18456 48 F Y N S Y 19.38 1 100 64 22 0.9 N 9.12 4.0 4.2 8.96
25 Mr.Raja                 18458 49 M N Y NS N 28.67 2 120 76 28 0.8 N 11.13 4.0 3.7 11.4
 
MASTER CHART 
NORMOTENSIVE INDIVIDUALS (CONTROL GROUP/ GROUP - B ) 
 BLOOD 
PRESSURE(mmHg ) 
S.No        NAME
Op/Ip 
No Age Sex Smoking Alcohol
Life 
style 
Family 
H/O 
BMI 
(Kg/m2)  
BMI 
GROUP Systolic Diastolic
Blood 
Urea  
(mg/dl) 
Serum 
Creatinine 
(mg/dl) 
USG  
Abd 
T . Sr. 
Calcium 
(mg/dl) 
Serum 
Phos 
(mg/dl) 
Serum 
Albumin 
(g/dl) 
C. Sr. 
Calcium  
(mg/dl)    
26                    Mrs.Ponniammal 18976 68 F N N NS N 30.14 2 106 60 30 0.7 N 9.72 3.8 4 9.72
27                    Mrs.Shankari 19234 51 F N N S N 21.8 1 110 70 27 0.8 N 9.24 4.3 3.9 9.32
28                    Mr.Chinnappan 19657 58 M Y N NS N 27.33 2 112 72 29 0.7 N 9.2 4.1 4.2 9.04
29                    Mrs.Sangeetha 19890 49 F N N NS Y 19.6 1 112 72 29 0.7 N 9.3 3.8 4 9.3
30                    Mr.Arokiyasamy 20023 56 M N Y S N 21.99 1 116 80 24 0.9 N 10.82 3.5 4.2 10.66
31                    Mr.James 20442 46 M Y Y S N 22.49 1 120 76 28 0.8 F 10.26 4.1 4.2 10.1
32                    Mr.Suppaiah 20897 75 M Y N NS N 19.38 1 110 70 27 0.8 N 10.1 3.9 3.5 10.5
33                    Mr.Srinivasan 21309 64 M N N NS N 27.33 2 106 60 30 0.6 N 8.2 3.7 4.5 7.8
34                    Mr.Karthik 21829 47 M Y Y S N 28.12 2 110 72 36 1 N 9.46 3.5 4.1 9.38
35                    Mr.Ismail 21952 47 M N Y NS N 29.06 2 122 76 22 1.1 N 9.96 3.9 4.1 9.88
36                    Mrs.Meena 22609 46 F N N NS N 28.12 2 112 72 29 0.7 N 9.64 3.6 3.8 9.8
37                    Mrs.Vasantha 24421 65 F N N S N 22.65 1 110 72 36 1 N 8.79 3.8 3.2 9.43
38                    Mrs.Bakkiyam 24838 45 F N N S N 28.62 2 106 74 28 0.7 N 8.45 4.4 3.4 8.93
39                    Mrs.Kamala 25148 56 F N N NS N 26.04 2 116 80 24 0.9 N 10.28 4.3 4 10.28
40                    Mrs.Chandra 25149 52 F N N NS Y 23.76 1 122 76 22 1.1 N 9.68 3.9 3.8 9.84
41                    Mrs.Naseer Begum 25183 60 F N N S N 31.25 2 120 78 26 0.8 N 8.47 4.6 3.9 8.55
42                    Mr.Samuel 25675 52 M Y Y S N 26.88 2 116 80 24 0.9 N 10.16 3.6 4.2 10
43                    Mr.Mani 25679 55 M N Y S N 21.12 1 122 76 22 1.1 N 9.2 3.8 4.5 8.8
44                    Mrs.Padmini 25987 78 F N N S N 20.8 1 110 72 36 0.8 N 9.1 2.9 3.5 9.5
45                    Mr.Lakshman 27456 64 M N Y NS Y 27.94 2 106 60 30 0.1 N 9.68 3.2 4.2 9.52
46                    Mrs.Rukhmani 27865 56 F N N NS N 20.95 1 100 64 22 0.9 N 10.96 3.2 4.8 10.32
47                    Mrs.Manjula 28134 36 F N N NS N 28.52 2 110 72 36 0.9 N 9.7 3.8 4.1 9.62
48                    Mr.Subramani 28675 78 M Y N NS N 21.45 1 120 76 28 0.8 F 10.01 4.1 4.3 9.77
49                    Mr.Sundarraj 40689 52 M N Y S Y 25.09 2 100 64 22 0.9 N 9.16 4.0 4.2 9.9
50                    Mr.Sivakolunthu 40862 27 M Y Y S Y 21.27 1 106 60 30 0.1 N 9.68 4.3 4 9.68
 
ABBREVIATION 
A I                         - Angiotensin I  
A II                        - Angiotensin II 
ACEIs                     -Angiotensin Converting Enzyme Inhibitors 
AMP                       -Adenosine Mono Phosphate 
ARBs                      - Angiotensin Receptor Blockers 
AT1                              - Angiotensin receptor 1. 
AT2                          - Angiotensin receptor 2. 
ATPase                    - Adenosine Tri Phosphatase 
BCG                         - BromoCresol Green  
BMI     - Body Mass Index 
BP                            - Blood Pressure 
Ca2+                          - Calcium  
CO                            - Cardiac Output  
CRP                          - C-Reactive Protein 
DAM                        - Diacetyl Monoxime  
DASH                      - Dietary Approach to Stop Hypertension 
DBP                         - Diastolic Blood Pressure 
ECG     - Electrocardiography 
ENaCs                      - Epithelial  Sodium  Channels 
H/o                            - History of 
HT                             - Hypertension 
ISH                            - Isolated Systolic Hypertension 
JNC                           -Joint National Committee 
K+                                               - Pottasium  
Mg2+                          - Magnesium 
MI                              - Myocardial Infarction  
Na+                             - Sodium  
NaCl                          - Sodium Chloride 
NADPH                     -Nicotinamide Adenine Dinucleotide 
                                                           Phosphate(Reduced) 
NHANES                   - National Health And Nutrition Examination Surveys 
NO                              - Nitric Oxide  
NOS                           - Nitric Oxide Synthase  
PCR                            - Protein Creatinine Ratio 
PIH                             - Pregnancy Induced Hypertension 
PR                              - Peripheral Resistance  
PTH                           - ParaThyroid Hormone  
RAAS                        - Renin-Angiotensin-Aldosterone System  
RBC                           - Red Blood Cells 
SBP                            - Systolic Blood Pressure 
TGF-β                        - Transforming Growth Factor – Beta 
WHO        - World Health Organization 
cm                               - Centimetre 
dl                                - Decilitre 
g                                  - Gram 
hr                                - Hour  
Kg       - Kilogram 
m2       - Metre square 
mg                              - Milligram 
min                             - Minute 
ml                               - Millilitre  
mm3       - Cubic millimetre 
mmHg                        - Millimeters of Mercury 
nm                              - Nanometre 
Yr                               - Year 
µL                          - Microlitre 
α                                 - Alpha 
β                                 - Beta 
%                                - Percentage 
&       - And 
<                                 - Less than 
>                     - More than 
±       - Plus or minus 
≤                                 - Less than or Equal 
≥                                 - More than or Equal  
 
MASTER CHART – ABBREVIATION 
 
S.No                               - Serial Number 
Ip/Op No:                       - Inpatient/Outpatient Number  
Age:    
Sex:                M – Male ;  F – Female  
Symptoms:                       G –  Giddiness  
                                          H – Headache  
                                        EF – Easy Fatigability 
                                          S – Syncope  
                                          E – Epistaxis  
                                          P – Palpitation  
Smoking:                          Y – Yes ;  N – No   
Alcohol:    Y – Yes  ; N – No 
Lifestyle:                           S – Sedentary  ; NS – Nonsedentary  
Family History:                 Y – Yes  ; N – No 
BMI:                                  Body Mass Index 
BMI Group:                       1 – BMI < 25 ; 2 – BMI > 25 
mmHg:                                Millimeters of Mercury. 
USG – Abd:                         N – Normal ; F – Fatty liver 
T.Sr.Calcium:                      Total Serum Calcium 
Serum Phos:                         Serum Phosphorus 
C . Sr. Calcium:                   Corrected Serum Calcium 
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